| UNITED STATES | ||||
| SECURITIES AND EXCHANGE COMMISSION | ||||
| Washington, D.C. 20549 | ||||
FORM 10-K
For the fiscal year ended December 31, 2019
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||
For the transition period from to
Commission file number: 000-33001
NATUS MEDICAL INCORPORATEDINCORPORATED
(Exact name of Registrantregistrant as specified in its charter)
| Delaware | ||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) | |
6701 Koll Center Parkway, Suite 120, Pleasanton, CA94566
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Securities Registered Pursuantregistered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value per share | NTUS | The |
| (The Nasdaq Global Select Market) | ||
Securities Registered Pursuantregistered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ý☒ No ¨☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨☐ No ý☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days. Yes ý☒ No ¨☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý☒ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large Accelerated Filer | ☒ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||
| Emerging growth company | ☐ | ||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨☐ No ý☒
As of June 30, 2018,2019, the last business day of Registrant’s most recently completed second fiscal quarter, there were 33,590,33734,040,230 shares of Registrant’s common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 29, 2018)28, 2019) was $1,158,866,627.$874,493,509. Shares of Registrant’s common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
On February 20, 2019,24, 2020, the registrant had 33,777,38834,105,116 shares of its common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the Registrant's Definitive Proxy Statement for the 20192020 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K, to be filed with the Securities and Exchange Commission, are incorporated by reference into Part III of this Annual Report on Form 10-K.
NATUS MEDICAL INCORPORATED
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
| ITEM 1. | ||
| ITEM 1A. | ||
| ITEM 1B. | ||
| ITEM 2. | ||
| ITEM 3. | ||
| ITEM 4. | ||
| ITEM 5. | ||
| ITEM 6. | ||
| ITEM 7. | ||
| ITEM 7A. | ||
| ITEM 8. | ||
| ITEM 9. | ||
| ITEM 9A. | ||
| ITEM 10. | ||
| ITEM 11. | ||
| ITEM 12. | ||
| ITEM 13. | ||
| ITEM 14. | ||
| ITEM 15. | ||
| ITEM 16. | ||
PART I
ITEM 1. Business
This Annual Report on Form 10-K (this “Annual Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated (“Natus,” “we,” “us,” or “the Company”“our”). These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 1 include, but are not limited to, statements regarding the effectiveness and advantages of our products, factors relating to demand for and economic advantages of our products, our plan to develop and acquire additional technologies, products or businesses, our marketing, technology enhancement, and product development strategies, our ability to complete all of our backlog orders, and the anticipated timing and effect of the implementation of our new organizational structure.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause our actual results to differ materially from those that we predicted in the forward-looking statements. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A for a description of risks and uncertainties that could cause actual results to differ from those that we predicted. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements, except as required by Federal Securities laws.
“Natus” and other trademarks of ours appearing in this report are our property.
Overview
Natus isprovides innovative healthcare solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.
Our broad product portfolio represents a leading providerheritage of neurology, newborninnovation and leadership. Natus brands have been setting the standard for patient care for over eighty (80) years. Our products are trusted by medical professionals in university medical centers, public and hearingprivate hospitals, physician offices, clinics, research laboratories, and balance assessment healthcareother sites around the world.
We use our clinical expertise to support our customers' evolving needs with advanced products, continuing education and services usedoutstanding technical service.
Natus provides product solutions for the screening, diagnosis, detection, treatment, monitoringthree end markets: Neuro, Newborn Care and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.Hearing & Balance.
On January 15, 2019, Natus announced the implementation of a new organizational structure designed to improve operational performance and make it a stronger, more profitable company.
Neuro—Includes products and services that provide diagnostic, therapeutic and surgical solutions in neurodiagnostics, neurocritical care and neurosurgery. Neuro's comprehensive neurodiagnostic solutions include electroencephalography (“EEG”) and long termlong-term monitoring (“LTM”), Intensive Care Unit (“ICU”) monitoring, electromyography (“EMG”), sleep analysis or polysomnography (“PSG”), and intra-operativeintraoperative monitoring (“IOM”). These solutions enhance the diagnosis of neurological conditions such as epilepsy, sleep disorders and neuromuscular diseases.
Our neurocritical care solutions include management of traumatic brain injury by continuous monitoring of intracranial pressure (“ICP”) and cerebrospinal fluid (“CSF”) drainage.drainage, as well as cranial access kits for entry into the cranium. Our neurosurgical solutions provide options that promotesuch as dural healinggrafts facilitate dural repair in the cranium as well as valves, shunts and related treatment solutions for procedures involving hydrocephalus. We acquired our neurocritical care and neurosurgical product lines from Integra LifeSciences in October 2017 (“Integra Asset Acquisition”).
Newborn Care—Includes products and services for newborn care including hearing screening, brain injury, ROP vision screening, thermoregulation,monitoring, eye imaging, jaundice management, and various disposable newborn care supplies, as well assupplies.
Hearing & Balance — The Hearing portfolio includes products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders.
a complete product and brand portfolio known for its sophisticated design technology in the hearing and balance assessment markets. We acquired the Otometrics business in January 2017.
Neuro
Our Neuro business unit representsportfolio is comprised of a comprehensive line of neurodiagnostic, neurocritical care, and neurosurgical products that are used by healthcare practitioners in the diagnosis and monitoring of neurological disorders of the central and peripheral nervous system.disorders. The environments in which these products are used include outpatient private practice facilities and inpatient hospital environments, includingenvironments. Our products can be used throughout the continuum of care through diagnostic procedures and monitoring of patients during admissions, surgery, while under sedation, in post-operative care, and in intensive care units. Our Neuro products and services include:
Neurodiagnostic
| • | Electroencephalography — Equipment, supplies and services used to monitor and visually display the electrical activity generated by the brain and other key physiological signals for both diagnosis and monitoring of neurological disorders in the hospital, research laboratory, clinician office and patient’s home. |
| • | Electromyography — Equipment and supplies used to measure electrical activity in nerves, muscles, and critical pathways includes EMG, nerve conduction and evoked potential functionality. |
| • | Polysomnography — Equipment and supplies used to measure a variety of respiratory and physiologic functions to assist in the diagnosis and monitoring of sleep disorders, such as insomnia and obstructive sleep apnea. |
| • | Intraoperative monitoring — Equipment and supplies used to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The goal of IOM is to provide real time guidance to the surgeon and anesthesiologist, which will reduce the risk to the patient during surgery. |
Neurocritical Care
| • | Intracranial pressure monitoring — Equipment and catheters used to monitor pressure in the cranium/brain and catheters to drain cerebrospinal fluid from the brain to aid in hydrocephalus and traumatic brain injury cases. |
| • | Cranial access kits — Convenient, pre-packaged sterile sets containing all necessary components for entry into the cranium, to monitor intracranial pressure and provide temporary drainage of CSF. |
Neurosurgery
| • | Shunts and Dural grafts — Shunts are used to manage the drainage of cerebrospinal fluid from the brain to maintain appropriate levels of CSF when treating hydrocephalus. Dural grafts are used in procedures to repair or substitute a patient's dura mater which surrounds the brain. |
Diagnostic EEG and Long-term Monitoring
We design, manufacture, and market a full line of instruments and supplies used to help diagnose the presence of seizure disorders and epilepsy, look for causes of confusion, evaluate head injuries, tumors, infections, degenerative diseases, and metabolic disturbances that affect the brain,brain; and assist in surgical planning. This type of testing is also done to diagnose brain death in comatose patients. These systems and instruments work by detecting, amplifying, and recording the brain’s electrical impulses, as well as other physiological signals needed to support clinical findings. Routine clinical EEG recording is done by placing electrodes on a patient’s scalp over various areas of the brain to record and detect patterns of activity and specific types of electrical events. EEG technologists perform the tests, and neurologists, neurophysiologists and epileptologists review and interpret the results.
Routine outpatient clinical EEG testing is performed in hospital neurology laboratories, private physician offices, and in ambulatory settings such as the patient’s home, providing physicians with a clinical assessment of a patient’s condition. Long-term inpatient monitoring of EEG and video to monitor behavior (LTM) is used to determine complex treatment plans, and for patients with seizures that do not respond to conventional therapeutic approaches, surgical solutions may be appropriate. Patients suffering from severe head trauma and other acute conditions that may affect the brain are monitored in ICUs. In addition, research facilities use EEG equipment to conduct research on humans and laboratory animals.
Diagnostic Electroencephalograph Monitoring Product Lines
Our EEG diagnostic monitoring product lines for neurology consist of signal amplifiers, workstations to capture and store synchronized video and EEG data, and proprietary software. These products are typically used in concert, as part of an EEG “system” by the neurology/neurophysiology department of a hospital or clinic to assist in the diagnosis and monitoring of neurological conditions.
| • | NeuroWorks; NicoletOne. Our EEG Systems include a broad range of products, from software licenses and ambulatory monitoring systems to advanced laboratory systems with multiple capabilities for EEG, ICU monitoring, |
| • | Stellate/Gotman Spike and Seizure; GridView; NicoletOne Trends. Our proprietary spike and seizure detection algorithm detects, summarizes, and reports EEG events that save health-care professionals time by increasing the speed and accuracy of interpretation. GridView is a tool that allows the clinician to correlate EEG patterns with electrode contacts on a 3D view of the patient brain using magnetic resonance (“MR”) or computed tomography (“CT”) images, thus enabling the visualization and annotation of the brain surface and internal structures involved in the diagnosis of epilepsy. NicoletOne Trends provides a comprehensive set of EEG analysis algorithms that are used to generate compressed trends of large amounts of data to assist in the clinical evaluation and data review process. |
| • | Proprietary Signal Amplifiers. Our proprietary signal amplifiers function as the interface between the patient and the computer. The headbox connects electrodes attached to the patient’s head to our EEG monitoring systems. |
| • | Nicolet Cortical Stimulator. This product is our proprietary device that provides cortical stimulation to the brain during functional brain mapping either before or during surgery to help the surgeon protect the eloquent parts of the brain (parts of the brain that control speech, motor and sensory functionality). The device can be used as a standalone unit or with the fully integrated NicoletOne or NeuroWorks software that supports control of the device from the software, automated mapping and comprehensive report generation. |
| • | Supplies. We also manufacture and market a full line of proprietary EEG electrodes and other supplies used in the electroencephalography field. |
Electrodiagnostic Monitoring
Our electrodiagnostic systems include EMG,electromyography (EMG), nerve conduction (“NCS”), and often evoked potential (“EP”) functionality. EMG and NCS involve the measurement of electrical activity of muscles and nerves both at rest and during contraction. Measuring the electrical activity in muscles and nerves can help diagnose diseases of the peripheral, central nervous system or musculature system. An electromyogram is doneperformed to determine if there is any disease present that effects muscle tissue, nerves, or the junctions between nerve and muscle (neuromuscular junctions). An electromyogram can also be used to diagnose the cause of weakness, paralysis, and muscle twitching, and is also used as a primary diagnosis for carpal tunnel syndrome, which is the most frequently encountered peripheral compressive neuropathy. EMG is also used for clinical applications of botox to relieve muscle spasm and pain. We market both the clinical system and the needles used for these procedures.
Electrodiagnostic Product Lines
| • | Dantec Keypoint. The Dantec Keypoint G-4 and Focus EMG and EP family of products features amplifiers, stimulators, and strong signal quality. The Keypoint G4 is used for advanced neurodiagnostic applications such as single fiber EMG, visual and auditory evoked potentials, and in routine nerve conduction studies. The Keypoint Focus system is also available in a portable laptop configuration. |
| • | Dantec Clavis. The Dantec Clavis device is a hand-held EMG stimulation device that provides muscle and nerve localization information to assist with medication and botox injections. In conjunction with the Bo-ject or Myoject hypodermic needle and electrodes, physicians can better localize the site of the injection. |
| • | Nicolet EDX family. A hardware platform of amplifiers, base control units, stimulators and hand-held probes that are sold with Nicolet brand proprietary software. These mid- to high-end systems have full functionality, strong signal quality, and flexibility. They include EMG, NCS, EP’s, IOM and advanced data analysis features. |
| • | Nicolet VikingQuest. An EMG system for the mid-range market. The device runs on our proprietary software. |
| • | Natus UltraPro. This is an entry level product with add on capabilities that offers high quality data collection using the Dantec Keypoint amplifiers and the proprietary Natus EMG/EP software. |
| • | Supplies. We also manufacture and market a full line of proprietary EMG needles and other supplies used in the electrodiagnostic field. |
Diagnostic Polysomnography Monitoring
with treatment devices using Positive Airway Pressure technology (“PAP”) during the sleep study and the proper settings for the treatment devices are determined. In many cases, the sleep study is performed in the patient’s home.
Diagnostic PSG Monitoring Product Lines
We market dedicated diagnostic PSG monitoring products that can be used individually or as part of a networked system for overnight sleep studies to assist in the diagnosis of sleep disorders. Additionally, we offer products that are specifically designed to be used in the patient’s home. Some of our EEG systems described above can also be configured to perform diagnostic PSG monitoring. These products include software licenses, ambulatory monitoring systems, and laboratory systems that combine multiple capabilities, including EEG monitoring, physician review stations, and quantitative PSG analysis capabilities.
| • | Embla REMlogic, Sandman; and Xltek SleepWorks. Our diagnostic PSG systems capture and store all data digitally. The systems enable users to specify rules and personal preferences to be used during analysis, summarizing the results graphically and incorporating them in detailed reports. |
| • | Proprietary Amplifiers. Our data acquisition systems incorporate recent developments in superior amplifiers for sleep analysis. Our amplifiers are used in both hospitals and stand-alone clinics. In addition to exceptional signal quality, headboxes include various tools such as built-in oximeters and controls to allow the user to start and stop a study or perform electrode impedance testing either at the patient’s bedside or from the monitoring room. |
| • | Supplies. We also market a broad line of supplies, disposable products and accessories for the PSG laboratory including the XactTrace respiratory monitoring belts. |
Intraoperative Monitoring
Intraoperative monitoring (“IOM”) is the use of electrophysiological methods such as EEG, EMG, and evoked potentials to monitor the functional integrity of certain neural structures (i.e. nerves, spinal cord and parts of the brain) during surgery. The purpose of IOM is to reduce the risk to the patient’s nervous system, and/or to provide functional guidance to the surgeon and anesthesiologist during surgery.
Diagnostic IOM Product Lines
| • | Xltek Protektor. The Protektor system is an IOM system that provides medical professionals with all information necessary to make immediate and critical surgical decisions. The system combines flexibility with multi-modality allowing full coverage of IOM techniques. The Protektor comes in 16 or 32 channel options. |
| • | Nicolet EDX. These combo systems are used in IOM applications where a smaller number of channels is sufficient. This approach is primarily followed in international markets that utilize the integrated system approach that allows for the use of the system in EMG clinical applications as well as in IOM applications. |
Neurocritical Care Products
Intracranial pressure and temperature provide insight into the health of the brain, especially in patients experiencing a traumatic brain injury, other traumatic, ischemic or hemorrhagic incidents, or a major neurosurgical procedure. A small hole is drilled into the braincranium to allow insertion of a catheter that contains a pressure/temperature or pressure only transducer that allows continuous monitoring of brain temperature and/or pressure.
| • | Camino ICP Monitor. The Camino ICP Monitor is a compact, portable device that provides tools for continuously determining and monitoring intracranial pressure and intracranial temperature. It has a touch screen interface, physiological alarms, and can output data to either a patient bedside monitor or to remote media types via a USB drive. These systems are used in the intensive care unit (ICU) environment. |
| • | Camino Catheters. Camino catheters use either fiber optic or strain gauge technology to measure either pressure and temperature or just pressure. Camino catheters measure their respective values at the tip of the catheter, which eliminates the need for a fluid-filled system that uses an external transducer to measure pressure. The Camino Flex Ventricular Intracranial Pressure Monitoring Kit has a catheter that allows both the measurement of ICP and CSF drainage. |
| • | Cranial Access Kits. Cranial Access Kits are convenient procedural kits that include all the instrumentation and items needed to access the subarachnoid space or the lateral ventricles of the brain. The kit is intended to be used with an external drainage and monitoring system in selected patients to reduce intracranial pressure, to provide temporary drainage of CSF, and to monitor ICP. The kit is a convenient, pre-packaged sterile set containing all necessary components for entry into the cranium and is available with or without drugs and with a variety of drill bits and instrumentation. |
Neurosurgical Products
During brain surgery, the dura of the brain may need to be repaired or replaced. A dural graft is used to serve as a dural substitute for the surgical repair of dural defects. Moreover, brain surgery is performed to place shunts in the brain to help drain excess CSF either externally or into the body for reabsorption to help treat hydrocephalus.
| • | DURAFORM. DURAFORM Dural Graft Implant is an absorbable collagen matrix to provide a soft, conforming, and easy to use dural substitute. This product is used in the operating room to provide repair of the dura mater and promote dural healing. |
| • | Shunts. Shunts are used in the operating room to provide solutions for hydrocephalus or brain trauma. Shunts are used to manage the drainage of cerebrospinal fluid from the brain to maintain appropriate levels of CSF when treating hydrocephalus. |
Newborn Care
Our newborn care business unit represents a line of products and services that are used by healthcare practitioners in the diagnosis and treatment of common medical ailments in newborn care, as well as other products used in newborn through adult populations, including hearing diagnostics and balance & mobility systems.care. Our products are organized in nineeight modalities and include:
| • | Newborn Hearing Screening — Products used to screen hearing in newborns. |
| • | Diagnostic Hearing Assessment — Products used to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages. |
| • | Jaundice Management — Products used to treat jaundice, the single largest cause for hospital readmission of newborns in the U.S. |
| • | Newborn Brain Injury — Products used to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status. |
| • | Eye Imaging — Systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. |
| • | Essentials — Products used in the everyday operation of neonatal intensive care unit (“NICU”) and well-baby nursery department within the hospital environment. |
| • | NICVIEW — Live streaming video for families with babies in the NICU that enables family members and approved friends to see the new baby, 24/7, from anywhere in the world - from any Internet connected device, within a secured environment. |
Newborn Hearing Screening
Hearing impairment is the most common treatable chronic disorder in newborns, affecting as many as five babies out of every 1,000 newborns. It is estimated that 20,000 hearing-impaired babies are born in the United States (“U.S.”) every year, and as many as 60,000 more in the rest of the developed world. Until the introduction of universal newborn hearing screening programs, screening was generally performed only on those newborns that had identifiable risk factors for hearing impairment. However, screening only those newborns with risk factors for hearing impairment overlooks approximately half of newborns with some level of hearing impairment.
Early identification of hearing impairment and early intervention has been shown to improve language development significantly. Undetected hearing impairment often results in the failure to learn, process spoken language, and speak.
Newborn Hearing Screening Techniques
The two traditional technologies used to screen newborns and infants for hearing impairment are auditory brainstem response and otoacoustic emissions.
Auditory brainstem response (“ABR”). ABR technology is the most accurate and comprehensive method for screening and diagnosing hearing impairment. ABR technology is based on detecting the brain’s electricelectrical impulses resulting from a specific auditory stimulus.
Otoacoustic emission (“OAE”). OAEs are sounds created by the active biomechanical processes within the sensory cells of the cochlea. They occur both spontaneously and in response to acoustic stimuli. OAE screening uses a probe placed in the ear canal to deliver auditory stimuli and to measure the response of the sensory cells with a sensitive microphone.
Newborn Hearing Screening Product Lines
Our newborn hearing screening product lines consist of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners. These hearing screening products utilize proprietary signal detection technologies to provide accurate and non-invasive hearing screening for newborns and are designed to detect hearing loss at 30 or 35 dB nHL or higher. Each of these devices is designed to generate a PASS or REFER result.
| • | ALGO 5 and 3i Newborn Hearing Screeners. These Automated Auditory Brainstem Responses (“AABR”) devices deliver thousands of soft audible clicks to the newborn’s ears through sound cables and disposable earphones connected to the instrument. Each click elicits an identifiable brain wave, which is detected by disposable electrodes placed on the head of the child and analyzed by the screening device. These devices use our proprietary AABR signal detection algorithm. |
| • | ABaer Newborn Hearing Screener. The ABaer, which is a PC-based newborn hearing screening device, offers a combination of AABR, OAE, and diagnostic ABR technologies in one system. |
| • | Echo-Screen. Our hand-held Echo-Screen products provide a choice or combination of proprietary ABR and OAE technologies that can also be used for children through adults. The Echo-Screen III device is a compact, multi-modality handheld hearing screener that is tightly integrated with audible Lite Hearing Screening Data Management. |
Hearing Screening Supply Products
For infection control, accuracy, and ease of use, the supply products used with our newborn hearing screening devices are designed as single-use, disposable products. Each screening supply product is designed for a specific hearing screening technology.
| • | ABR Screening Supply Kits. Each ABR screen is carried out with single-use earphones and electrodes, which are alcohol and latex-free. The adhesives used in these supply products are specially formulated for use on the sensitive skin of newborns. To meet the needs of our customers we offer a variety of packaging options. Echo-Screen and ABaer offer the choice of either an earphone or use of ear tips for perform ABR screening. |
| • | OAE Supply Products. Each OAE screen is carried out with single-use ear tips that are supplied in a variety of sizes and packaging options. |
Peloton Screening Services
Peloton Screening Services is a nationwide service offering that provides hearing screening services to hospital-based customers. The core platform of the program meets the objectives of today’s healthcare environment by aligning with family centered care principals and Joint Committee on Infant Hearing (JCIH) recommendations. Peloton compliments our newborn hearing screening product lines and provides all aspects of a comprehensive service program: equipment, supplies, professional oversight by nurses or audiologists, screening personnel, case management, quality review & oversight, and state data management reporting.
Jaundice Management
The American Academy of Pediatrics estimates that each year 60% of the approximately four million newborns in the U.S. become jaundiced. According to the Journal of the American Medical Association, neonatal jaundice is the single largest cause for hospital readmission of newborns in the U.S., and accounts for approximately 50% of readmissions. Because of the serious consequences of hyperbilirubinemia, the American Academy of Pediatrics recommends that all newborns be closely monitored for jaundice and that phototherapy is the standard of care for the treatment of hyperbilirubinemia. The guidelines further recommend that all nurseries
have the necessary equipment to provide intensive phototherapy, and specifically recommend the use of the “blue” light as incorporated into our neoBLUE products.
Jaundice Management Products
| • | neoBLUE Product Family. This product line consists of our neoBLUE Overhead, neoBLUE Mini, neoBLUE Cozy, neoBLUE Compact and neoBLUE blanket devices, which utilize light emitting diodes (“LEDs”) to generate a high-intensity, narrow spectrum of blue light that is clinically proven to be most effective in the treatment of newborn jaundice. Our neoBLUE phototherapy devices emit significantly less ultraviolet light and heat than conventional phototherapy devices, reducing the risk of skin damage and dehydration for infants undergoing treatment. Because of the high intensity of these lights, the treatment time associated with phototherapy is reduced. |
Newborn Brain Injury
For many years, newborn infants admitted to the NICU of a hospital have been routinely monitored for heart activity, temperature, respiration, oxygen saturation, and blood pressure. Recently it has also been considered important to monitor brain activity. A cerebral function monitor, utilizing amplitude-integrated EEGs (“aEEGs”), is a device for monitoring background neurological activity. Our simplified aEEG devices, introduced over ten years ago, allow neonatologistsare designed to be simple for use by nurses and nurses to set-up and interpret basic neurological traces without neurology oversight.neonatologists.
Newborn Brain Injury Products
Our newborn brain injury products record and display parameters that the neonatologist uses to assess and monitor neurological status in the newborn. These devices continuously monitor and record brain activity, aiding in the detection and treatment of HIEhypoxic-ischemic encephalopathy ("HIE"), and seizures. The devices also monitor the effects of drugs and other therapies on brain activity and improve the accuracy of newborn neurological assessments. They are used with electrodes attached to the head of the newborn to acquire an EEG signal that is then filtered, compressed, and displayed graphically on the device or as a hardcopy printout. The monitors have touch screens for easy navigation and onscreen keyboards for data entry at the bedside.
| • | Olympic Brainz Monitor. The Olympic Brainz Monitor is our latest generation Cerebral Function Monitor. The device can be used in single-channel, two-channel or three-channel modes to continuously monitor and record brain activity. |
Eye Imaging
Our RetCam devices incorporate a camera combined with proprietary imaging software that are used to diagnose and monitor a range of ophthalmic maladies in premature infants. RetCam specializes in NICU ophthalmic imaging used in the detection of retinopathy of prematurity (ROP) and Retinoblastoma (RB) in newborns. ROP and RB are diseases of the retina that muchmust be detected very early after birth and treated immediately, so the RetCam diagnostic camera is a fundamental tool in preventing vision loss and total blindness in infants.
Eye Imaging Products
RetCam images enableassist physicians to assist in the evaluation of pediatric ocular disease, which have preserved the vision in thousands of infants. Each of the RetCam systems deliver objective and interpretable detail, allow image comparison over time, enable remote consultations, and provide reliable and defensible medico-legal documentation.
| • | RetCam 3. Full-featured imaging system with a range of interchangeable lenses, Fluorescein Angiography module option. |
| • | RetCam Shuttle. Laptop-based system with a smaller cart and dual wheel casters for improved transportability. |
| • | RetCam Portable. Laptop-based version in a case for maximum portability. |
Essentials
The Newborn Care Essentials products include such items as: Biliband®Biliband eye protectors, GumDrop® pacifiers, MiniMuffs®MiniMuffs noise attenuators, NeatNick®NeatNick heal lancets, Olympic®Olympic Circumstraint, Olympic®Olympic Papoose Boards, Olympic®Olympic Smart Scales, OraSwab, Save the Gonads®Gonads x-ray protection devices and SugarPlum®SugarPlum glucose lancets.
Live Video Streaming
Live Video Steaming Products
Hearing & Balance
Our solutions portfolio covers key application areas within hearing assessment, hearing screening, hearing instrument fitting and balance assessment. Many of the Otometricsour hearing and balance care solutions have set precedent within the hearing care industry and are used by thousands of clinicians around the world.
As an independent provider of hearing care diagnostic solutions, Otometrics workswe work closely with leading hearing aid manufacturers to develop new solutions within hearing assessment and hearing aid fitting.
Hearing Assessment
From otoacoustic emissions (OAE) and immittance screening to advanced audiological testing and 3D digital ear scanning, Otometrics offerswe offer a wide range of flexible devices and PC-based solutions that are designed to screen, test and assess patients of all ages. OtometricsOur hearing assessment solutions offer a range of functionality to support basic audiometric testing to advanced tinnitus and pediatric hearing assessment. HearingOur hearing care solutions by Otometrics help streamline the hearing screening and assessment process making it easier and convenient for the professional and the patient. OtometricsWe also manufacturersmanufacturer and marketsmarket a broad line of supplies and disposable products and accessories for hearing assessment.
Hearing Instrument Fitting and Verification
Hearing fitting solutions help professionals manage the entire hearing aid fitting process - from fitting and verifying the hearing aid to patient counseling and follow up. Used by thousands of hearing aid dispensers, audiologists and clinicians around the world, Otometricsour fitting solutions support otoscopy, audiometry, hearing aid testing and programming, fitting and verification with wireless design and binaural fitting capability. OtometricsOur fitting solutions are PC-based Noah-compatible and supported by integrated audiometric software that helps to streamline the fitting process for greater efficiency and patient satisfaction. OtometricsWe also manufacturers and marketsmarket a broad line of supplies and disposable products and accessories for hearing instrument fitting and verification.
3D Digital Ear Scanning
Audiometric Sound Rooms
Cam-Lock assembly system, high performance/low profile floor, window in the door, and excellent attenuation and acoustic capabilities to ensure acoustic performance, efficient workflow and maximum testing comfort.
Balance Assessment
Professionals who evaluate patients with balance disorders use Otometrics'our vestibular diagnostic and ENG/VNG (electronystagmography/videonystamography) systems and services. These solutions are used by audiologists, otolaryngologists, otologists and neurologists for identifying auditory and vestibular abnormalities. OtometricsOur balance care solutions are compact and include the world's first portable, gold standard video head impulse test (“vHIT”) and offer modular functionality to support vHIT, video frenzel, positional, oculomotor and SHIMP (suppression head impulse) testing. OtometricsWe also manufacturersmanufacture and marketsmarket a broad line of supplies, disposable face cushions, and accessories for balance assessment.
Segment and Geographic Information
We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Historically, our operating segments were based on three strategic business units. In January 2019, we announced the transition of our operating structure from three strategic business units to a single, unified company with globally-led operational teams in Sales and Marketing, Manufacturing, Research and Development, Quality, and General and Administrative functions.
Following the reorganization, we operate inas one operating segment and one reportable segment, which we have presented as the aggregation of our neuro, newborn care, and otometrics product families. Within this reportable segment we are organized on the basis of theprovides healthcare products, and services we provide which are usedfocused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Financial information is reviewed on a consolidated basis for purposes of making operating decisions and assessing financial performance. Consolidated financial information is accompanied by disaggregated information about revenues by end market and geographic region. We do not assess the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, and sleep disorders.
Information regarding our salesrevenues and long-lived assets in the U.S. and in countries outside the U.S. is contained in Note 19—20—Segment, Customer and Geographic Information of our Consolidated Financial Statements included in this report and is incorporated in this section by this reference.
Revenue by Product FamilyMarket and Product Category
For the years ended December 31, 2019, 2018 2017 and 2016,2017, revenue from our product familiesmarkets as a percent of total revenue was approximately as follows:
| Year Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2018 | 2017 | 2016 | 2019 | 2018 | 2017 | |||||||||||
| Neuro | 53 | % | 48 | % | 62 | % | 58 | % | 53 | % | 49 | % | ||||
| Newborn Care | 23 | % | 29 | % | 38 | % | 22 | % | 25 | % | 31 | % | ||||
| Otometrics | 24 | % | 23 | % | — | % | ||||||||||
| Hearing & Balance | 20 | % | 22 | % | 20 | % | ||||||||||
| Total | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | ||||
We also look at revenue as either being generated from sales of Devices and Systems, which are generally non-recurring, or related Supplies and Services, which are generally recurring. The products that are attributable to these categories are described above. Revenue from Devices and Systems, Supplies and Services as a percent of total revenue for the years ending December 31, 2019, 2018 2017 and 20162017 is as follows:
| Year Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2018 | 2017 | 2016 | 2019 | 2018 | 2017 | |||||||||||
| Devices and Systems | 72 | % | 71 | % | 63 | % | 74 | % | 72 | % | 67 | % | ||||
| Supplies | 22 | % | 22 | % | 28 | % | 22 | % | 22 | % | 26 | % | ||||
| Services | 6 | % | 7 | % | 9 | % | 4 | % | 6 | % | 7 | % | ||||
| Total | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | ||||
In 2019, 2018 2017 and 2016,2017, no single end-user customer comprised more than 10% of our revenue.
Backlog
In general, the company doeswe do not manufacture itsour products against a backlog of orders and doesdo not consider backlog to be a significant indicator of the level of future sales activity. Production and inventory levels are based on the level of incoming orders as well as projections of future demand. Therefore, the company believeswe believe that backlog information is not meaningful to understanding itsour overall business and should not be considered a reliable indicator of the company'sour ability to achieve any particular level of revenue or financial performance.
Marketing and Sales
Marketing
Our marketing strategy differentiates our productsstrategies differ by their levelproduct market, incorporating market dynamics, trends and competition in the positioning, promotion and pricing of each product. The value proposition that we communicate is focused on the quality, clinical performance, and customer benefit. We educateinvest in educating our customers worldwide about our products through trade conferences and direct presentations to healthcare professionals.
Domestic Direct and Distributor Sales
We sell our products in North America primarily through a direct sales organization. We believe this direct sales organization allows us to maintain a higher level of customer service and satisfaction than would otherwise be possible by other distribution methods. We also sell certain products under private label and distribution arrangements.
For the years ended December 31, 2019, 2018 2017 and 2016,2017, domestic revenue as a percent of total revenue was approximately as follows:
| Year Ended December 31, | ||||||||
| 2018 | 2017 | 2016 | ||||||
| Domestic revenue | 56.7 | % | 54.1 | % | 65.6 | % | ||
| Year Ended December 31, | ||||||||
| 2019 | 2018 | 2017 | ||||||
| Domestic revenue | 59.0 | % | 56.7 | % | 54.1 | % | ||
International Direct and Distributor Sales
We sell some of our products outside the U.S. through direct sales channels in Australia, Canada, China, Denmark, France, Germany, Italy, the Netherlands, New Zealand, the Nordics (Finland, Sweden, Norway), Spain, and the United Kingdom and parts of Latin America;Kingdom; we sell other products in those regions and into more than 100 other countries through a distributor sales channel.
For the years ended December 31, 2019, 2018 2017 and 2016,2017, international revenue as a percent of total revenue was approximately as follows:
| Year Ended December 31, | ||||||||
| 2018 | 2017 | 2016 | ||||||
| International revenue | 43.3 | % | 45.9 | % | 34.4 | % | ||
| Year Ended December 31, | ||||||||
| 2019 | 2018 | 2017 | ||||||
| International revenue | 41.0 | % | 43.3 | % | 45.9 | % | ||
We sell products to our distributors under substantially the same terms as sales through our direct sales channels. Terms of sales to international distributors are generally “ex works,” where title and risk of loss are assumed by the distributor at the shipping point. Distributors are generally given exclusive rights in their territories to purchase products from Natus and to resell to end users or sub-distributors.sub-distributors in their respective markets. Our distributors typically perform marketing, sales, and technical support functions in their respective markets. Each distributor may sell Natus products to their customer directly, via other distributors or resellers, or both. We actively train our distributors in product marketing, selling, and technical service techniques.
Seasonality in Revenue
We experience seasonality in our revenue. Demand for our products is historically higher in the second half of the year compared to the first. Our seasonality results from the purchasing habits of our hospital-based customers, whose purchases are often governed by calendar year budgets.
Group Purchasing Organizations
More than 90% of the hospitals in the U.S. are members of group purchasing organizations (“GPO”s), which negotiate volume purchase agreements for member hospitals, group practices, and other clinics.
For the years ended December 31, 2019, 2018 2017 and 2016,2017, revenue from direct purchases byunder a GPO memberscontract as a percent of total revenue was approximately as follows:
| Year Ended December 31, | ||||||||
| 2018 | 2017 | 2016 | ||||||
| Direct purchases by GPO members | 13.3 | % | 14.5 | % | 12.3 | % | ||
| Year Ended December 31, | ||||||||
| 2019 | 2018 | 2017 | ||||||
| Direct purchases by GPO members | 18.7 | % | 13.3 | % | 14.5 | % | ||
Third-Party Reimbursement
In the U.S., healthcare providers generally rely on third-party payors, including private health insurance plans, federal Medicare, state Medicaid, and managed care organizations, to reimburse all or part of the cost of the procedures they perform. Third-party payors can affect the pricing or the relative attractiveness of our products by regulating the maximum amount of reimbursement these payors provide for services utilizing our products. In addition, our Peloton hearing screening service is dependent on third-party payors to reimburse us for services provided.
Customer Service and Support
We generally provide a one-year warranty on our medical device and system products. We also sell extended service agreements on our medical device and system products. Service, repair, and calibration services for our domestic customers are provided by Company-owned service centers and our field service specialists. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
Manufacturing
We purchase materials and components from qualified suppliers that are subject to our quality specifications and inspections. We conduct quality audits of our key suppliers, several of which are experienced in the supply of components to manufacturers of finished medical devices, or supplies for use with medical devices. Most of our purchased components are available from more than one supplier.
Our manufacturing, service, and repair facilities are subject to periodic inspection by local and foreign regulatory authorities. Our quality assurance system is subject to regulation by the U.S. Food and Drug Administration (“FDA”) and other government agencies. We are required to conduct our product design, testing, manufacturing, and control activities in conformance with the FDA’s quality system regulations and to maintain our documentation of these activities in a prescribed manner. In addition, our production facilities have received International Organization for Standardization (“ISO”) 13485 certification. ISO 13485 certification standards for quality operations have been developed to ensure that medical device companies meet the standards of quality on a worldwide basis. We have also received the EC Certificate pursuant to the European Union Medical Device Directive 93/42/EEC, which allows us to place a CE mark on our products.
Research and Development
We are committed to introducing new products and supporting current product offerings in our markets through a combination of internal as well as external efforts that are consistent with our corporate strategy.
Internal product development capabilities. We believe that product development capabilities arethe ability to develop innovative products is essential to provideproviding our customers with new product offerings. We plan to leverage our core technologies by introducing product line extensions as well as new product offerings.
Partnerships that complement our expertise. We continue to seek strategic partners in order to develop products that may not otherwise be available to us. By taking advantage of our core competencies, we believe that we can bring acquired or distributed products to market in an efficient manner and leverage our distribution channels.
New opportunities through technology acquisition. We continue to evaluate new, emerging, and complementary technologies in order to identify new product opportunities. With our knowledge of our current markets we believe that we can effectively develop acquired technologies into successful new products.
Proprietary Rights
We protect our intellectual property through a combination of patent, copyright, trade secret, and trademark laws. We attempt to protect our intellectual property rights by filing patent applications for new features and products we develop. We enter into confidentiality or license agreements with our employees, consultants, and corporate partners, and seek to control access to our intellectual property, distribution channels, documentation, and other proprietary information. However, we believe that these measures afford only limited protection.
The intellectual rights to some of the original patents for technology incorporated into our products are now in the public domain. However, we do not consider these patents, or any currently viable patent or related group of patents, to be of such importance that their expiration or termination would materially affect our business.
We capitalize the cost of purchased technology and intellectual property, as well as certain costs incurred in obtaining patent rights, and amortize these costs over the estimated economic lives of the related assets.
We have severalnumerous registered trademarks and service marks. Our marks are pending or registered trademarks in the United States and several foreign countries. We intend to file for additional trademarks to strengthen our trademark rights, but we cannot be certain that our trademark applications will result in registration or that our trademarks will be enforceable.
Competition
We sell our products in competitive and rapidly evolving markets. We face competition from other companies in all of our product lines. Our competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
We derive a significant portion of our revenue from the sale of disposable supplies that are used with our medical devices. In the U.S., we sell our supply products in a mature market and we expect that our products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and profit margins.
We believe the principal factors that will draw clinicians and other buyers to our products, include:
Time required to obtain results with the product, such as to test for or treat a clinical condition;
Relative ease of use of the product;
Quality of customer support for the product;
Frequency of product updates;
Extent of third-party reimbursement of the cost of the product or procedure;
Extent to which the products conform to standard of care guidelines; and
Price of the product.
We believe that our primary competitive strength relates to the clinical functionality and reliability of our products. Different competitors may have competitive advantages in one or more of the categories listed above and they may be able to devote greater resources to the development, promotion, and sale of their products.
Government Regulation
FDA’s Premarket Clearance and Approval Requirements
Unless an exemption applies, the medical devices we sell in the United States, must first receive one of the following types of FDA premarket review authorizations under the Food, Drug, and Cosmetics Act, as amended:
Clearance via Section 510(k); or
Premarket approval via Section 515 if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA’s 510(k) clearance process usually takes from three to six months, but can take longer. The process of obtaining premarket approval via Section 515 is much more costly, lengthy, and uncertain. Premarket approval generally takes from one to three years, but can take longer. We cannot be sure that the FDA will ever grant either 510(k) clearance or premarket approval for any product we propose to market in the United States.
The FDA decides whether a device must undergo either the 510(k) clearance or premarket approval process based upon statutory criteria. These criteria include the level of risk that the FDA perceives to be associated with the device and a determination of whether the product is a type of device that is substantially equivalent to devices that are already legally marketed. The FDA places devices deemed to pose relatively less risk in either Class I or Class II, which requires the manufacturer to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. The premarket notification under Section 510(k) must demonstrate that the proposed device is substantially equivalent in intended use and in safety and effectiveness to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications.
The FDA places devices deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed to be not substantially equivalent to a predicate device, in its Class III classification. The FDA requires these devices to undergo the premarket approval process via Section 515 in which the manufacturer must prove the safety and effectiveness of the device. A premarket approval application must provide extensive pre-clinical and clinical trial data.
The FDA may require results of clinical trials in support of a 510(k) submission and generally requires clinical trial results for a premarket approval application. In order to conduct a clinical trial on a significant-risk device, the FDA requires manufacturers to apply for and obtain, in advance, an investigational-device exemption. The investigational-device exemption application must be supported by appropriate data, such as animal and laboratory testing results. If the FDA and the Institutional Review Boards at the clinical trial sites approve the investigational-device exemption application for a significant-risk device, the manufacturer may begin the clinical trial. An investigational-device exemption approval provides for a specified clinical protocol, including the number of patients and study sites. If the manufacturer deems the product a non-significant risk device, the product will be eligible for more abbreviated investigational-device exemption requirements. If the Institutional Review Boards at the clinical trial sites concur with the non-significant risk determination, the manufacturer may begin the clinical trial.
Most of our products have been cleared by the FDA as Class II devices.
FDA Regulation
Numerous FDA regulatory requirements apply to our products. These requirements include:
FDA quality system regulations which require manufacturers to create, implement, and follow design, testing, control, documentation, and other quality assurance procedures;
Medical device reporting regulations, which require that manufacturers report to the FDA certain types of adverse and other events involving their products; and
FDA general prohibitions against promoting products for unapproved uses.
Class II and III devices may also be subject to special controls applied to them, such as performance standards, post-market surveillance, patient registries, and FDA guidelines that may not apply to Class I devices. We believe we are in compliance with applicable FDA guidelines, but we could be required to change our compliance activities or be subject to other special controls if the FDA changes existing regulations or adopts new requirements.
We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to adequately comply, the FDA can institute a wide variety of enforcement actions, including:
Issuance of a Form 483 citation;
Fines, injunctions, and civil penalties;
Recall or seizure of our products;
Issuance of public notices or warnings;
Imposition of operating restrictions, partial suspension, or total shutdown of production;
Refusal of our requests for 510(k) clearance or pre-market approval of new products;
Withdrawal of 510(k) clearance or pre-market approval already granted; or
Criminal prosecution.
The FDA also has the authority to require us to repair or replace any misbranded or adulterated medical device manufactured or distributed by us.
Other Regulations
We also must comply with numerous additional federal, state, and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, biohazards, fire hazard control, and hazardous substance disposal. We believe we are currently in compliance with such regulations.
Countries outside of the U.S. regulate medical devices in a manner similar to that of the FDA. Our manufacturing facilities are subject to audit and have been certified to be ISO 13485:2016, Medical Device Directive 93/42/EEC, and MDSAP compliant, which allows us to sell our products in Europe, Canada, Europe, and other territories around the world. All of our manufacturing facilities are subject to inspection by our notified bodies or other competent authorities, and in some cases without advance notice. We plan to seek approval to sell our products in additional countries, while maintaining our current approvals. The time and cost of obtaining new, and maintaining existing, market authorizations from countries outside of North America, and the requirements for licensing products in these countries may differ significantly from FDA requirements.
In 2017, the European Union ("EU")adopted the EU Medical Device Regulation (Council Regulations 2017/745) which imposes stricter requirements for the marketing and sale of medical devices, including new quality system and post-market surveillance requirements. The regulation has a three-year implementation period toending in May 2020 and will replace the existing directives on medical devices in the EU. After May 2020, medical devices marketed in the EU will require certification according
to these new requirements, except that devices with valid CE certificates, issued pursuant to the Medical Device Directive before May 2020, may be placed on the market until 2024. Complying with this new regulation will requirerequires us to incur significant costs on product design history file remediation and failuretransition. Failure to meet the requirements of the regulation could adversely impact our business in the European Union and other countries that utilize or rely on European Union requirements for medical device registrations.
Employees
On December 31, 2018,2019, we had approximately 1,7291,484 full time employees worldwide. In Argentina, some of our productionOur employees in Germany are represented by labor unions and our employees in Germany have established a works council.Works Council. We have not experienced any work stoppages, and we consider our relations with our employees to be good.
Executives
The following table lists our executive officers and their ages as of March 1, 2019:2, 2020:
| Name | Age | Position(s) | |||
| Jonathan A. Kennedy | President and Chief Executive Officer | ||||
| B. Drew Davies | Executive Vice President and Chief Financial Officer | ||||
D. Christopher Chung, M.D. | Vice President of Quality, Regulatory Affairs and Chief Medical | ||||
Austin F. Noll, III | Executive Vice President and Chief Commercial Officer | ||||
Jonathan A. Kennedy has served as Chief Executive Officer, and as a member of the Board of Directors since July 2018. Mr. Kennedy joined Natus as Senior Vice President and Chief Financial Officer in April 2013 and was appointed Executive Vice President and Chief Financial Officer in September 2016. In addition, he currently serves on the Board of Directors for IRadimed Corporation. Before joining Natus, Mr. Kennedy was Senior Vice President and Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005 and Director of Finance since 2004. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc. and Harris Corporation. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida. Mr. Kennedy is also a Certified Public Accountant.
B. Drew Davies joined Natus as Executive Vice President and Chief Financial Officer in October 2018. Mr. Davies most recently served as Executive Vice President and Chief Financial Officer of Extreme Networks since June 2016. Before joining Natus, Mr. Davies served as Vice President and Corporate Controller at Marvell Semiconductor Inc. from December 2015 until May 2016. Prior to that, Mr. Davies was the Senior Vice President, Corporate Controller at Spansion, Inc. from August 2012 to December 2015. Prior to Spansion, Mr. Davies was Corporate Controller at Intersil Corporation from April 2009 to August 2012, and served as Operations Controller from March 2008 to April 2009. Mr. Davies also served as Chief Financial Officer of Nanoconduction, Inc. from March 2007 to March 2008, Director of Finance and Administration for STATSChipPac from September
1999 to March 2007, held various finance roles at Micron Custom Manufacturing Services from November 1992 to September 1999. Mr. Davies holds a Master of Business Administration degree from Santa Clara University and a Bachelor of Science, Business Accounting degree from the University of Idaho.
D. Christopher Chung, joined Natus in 2000 as the Medical Director. He has also served as Vice President of R&D and most recently since 2011 as Vice President Medical Affairs, Quality and Regulatory. From 2000 to 2007, Dr. Chung also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco providing patient care in the Neonatal Intensive Care Unit and Newborn Nursery. From 1997 to 2000, Dr. Chung trained as a pediatric resident at Boston Children’s Hospital and Harvard Medical School. From 1986 to 1993, Dr. Chung worked as an R&D engineer at Nellcor Incorporated, a medical device company that pioneered the development of pulse oximetry. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is board certified in Pediatrics and is a Fellow of the American Academy of Pediatrics. Dr. Chung has also been awarded nine U.S. Patents in the medical device field.
Austin F. Noll, III joined Natus in August 2012 as the Vice President and General Manager, Neuro. Prior to joining Natus, Mr. Noll served as the President and CEO of Simpirica Spine, a California-based start-up company that developed and commercialized a novel device for spinal stabilization. Prior to joining Simpirica Spine, Mr. Noll served as the President and CEO of NeoGuide Systems, a medical robotics company acquired by Intuitive Surgical. Prior to joining NeoGuide Systems, Mr. Noll held numerous management positions at Medtronic over a 13-year period, where he served as the Vice President and General Manager of the Powered Surgical Solutions and the Neurosurgery businesses. Before Medtronic, he held sales positions at C.R. Bard and Baxter Healthcare. He received a Bachelor of Science degree in Business Administration from Miami University and a Master of Business Administration degree from the University of Michigan.
Other Information
Natus was incorporated in California in May 1987 and reincorporated in Delaware in August 2000.
We maintain corporate offices at 6701 Koll Center Parkway Suite 120, Pleasanton, California 94566. Our telephone number is (925) 223-6700. We maintain a corporate website at www.natus.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.
We make available, free of charge on our corporate website, copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC’s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Stock Market under the symbol “BABY”“NTUS”.
Item 1A. Risk Factors
Risks Related to Our Business and Industry
Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
On January 15, 2019 Natus announced the implementation of a new organizational structure, “One Natus,” designed to improve operational performance and make it a stronger, more profitable company. ThereWhile the implementation is substantially complete, there can be no assurance that we will realize, in full or in part, the anticipated benefits of this new structure. Our financial goals assume a level of increased productivity. If we are unable to deliver these expected improvements, or continue to invest in business growth, or if the volume and nature of change require additional resources, our business operations and financial results could be materially and adversely impacted. Our ability to successfully manage and execute these initiatives and realize expected savings and benefits in the amounts and at the times anticipated is important to our business success. Any failure to do so, which could result from our inability to successfully execute organizational change and business transformation plans, changes in global or regional economic conditions, competition, changes in the industries in which we compete, unanticipated costs or charges, loss of key personnel and other factors described herein, could have a material adverse effect on our businesses, financial condition and results of operations.
Our growth in recentprior years has depended substantially on the completion of acquisitions and we may not be able to complete acquisitions of the same nature or relative size in the future to support a similar level of growth.
The acquisitions that we have completed have contributed to our growth in recentprior years. We have expended considerable effort in seeking to identify attractive acquisition candidates, and ultimately, to negotiate mutually agreeable acquisition terms.
The market for attractive acquisitions is competitive and others with different strategic objectives or greater financial resources than we have may be better positioned than we are to acquire desirable targets. Further, we may not be able to negotiate acquisition terms with target companies that will allow us to achieve acceptable financial returns from the transaction.
•Revision of previously filed financial statements;
•Failure to manage a smooth transition tomeet our reporting obligations;
•Loss of investor confidence; and
•Negative impact on the new systems and the ongoing operations and supporttrading price of the new systems could materially harm our business operations.
If we are not able to maintain effective internal control over financial reporting in the future, the accuracy and timeliness of our financial reporting may be adversely affected.
A material weakness is defined under the standards issued by the Public Company Accounting Oversight Board as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected and corrected on a timely basis. We
We reported a material weakness in our internal control over financial reporting for the year ended December 31, 2017 related to missing controls over a significant business combination, which we remediated in 2018. Separately,Separate from the material weakness identified for the year ended December 31, 2017, during the fourth quarter of 2018, in connection with a change in control owner, management identified an existing control that was not designed at a sufficient precision to adequately review our analysis of separate reporting units, which could have resulted in a material misstatement. Although we took steps to remediate both these issues in 2018 and believe thatboth material weaknesses were remediated as of December 31, 2018, these measures may not be sufficient to avoid similar weaknesses or other deficiencies in the future. For additional information on the material weakness identified in
During the fourth quarter of 2018, see2019, we identified errors as part of closing our books and concluded that certain deficiencies existed in the “Management's ReportCompany’s internal control over financial reporting. Specifically, we did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of our controls over payroll accounts contributed to an error in the period end accrual. The Company has concluded that these deficiencies could have resulted in a material misstatement of the consolidated financial statements that would not have been prevented or detected on Internal Control Over Financial Reporting” sectiona timely basis, and as such, these control deficiencies resulted in a material weakness in our internal control over financial reporting. We plan to make substantive changes to enhance our design of “Item 7A. Quantitativecontrols intended to identify and Qualitative Disclosures About Market Risk”assess contracts that include research and development and to aid in this Annual Report.confirming the accuracy of the payroll accrual accounts. There can be no assurances that these remediation steps will be successful.
The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and disclosure controls and procedures quarterly. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. If other material weaknesses are identified in the future or we are not able to comply with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated or could be restated, we could receive an adverse opinion regarding our controls from our independent registered accounting firm and we could be subject to
investigations or sanctions by regulatory authorities, which would require additional financial and management resources, and the market price of our stock could decline.
Our operating results may decline if we do not succeed in developing, acquiring, and marketing additional products or improving our existing products.
We intend to develop additional products and technologies, including enhancements of existing products, for the screening, detection, treatment, monitoring and tracking of common medical ailments. Developing new products and improving our existing products to meet the needs of current and future customers requires significant investments in research and development. Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials, which can be time consuming and expensive. Unfavorable or inconsistent clinical data from existing or future clinical trials may adversely affect our ability to secure marketing authorization for certain products. Furthermore, all results, even positive ones, are subject to the interpretation of FDA and other regulatory agencies. If we fail to successfully sell new products, update our existing products, or timely react to changes in technology, our operating results may decline as our existing products reach the end of their commercial life cycles.
Adverse economic conditions in markets in which we operate may harm our business.
Unfavorable changes in U.S. and international economic environments may adversely affect our business and financial results. Concerns over the economic stability, the level of U.S. national debt, currency fluctuations and volatility, the rate of growth of Japan, China, and other Asian economies, unemployment, the availability and cost of credit, inflation levels, trade relations, energy costs and geopolitical uncertainty have contributed to increased volatility and diminished expectations for the economy and the markets. During challenging economic times, and in tight credit markets, our customers may delay or reduce capital expenditures. This could result in reductions in sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies, and increased price competition, all of which could impact our results of operations and financial condition. In addition, we expect these factors will cause us to be more cautious in evaluating potential acquisition opportunities, which could hinder our ability to grow through acquisition while these conditions persist.
In addition, we are susceptible to risks related to the outbreak of a novel strain of coronavirus (“COVID-19”) in China and its spread to other countries. In particular, the continued spread of COVID-19 globally could adversely affect our operations, including our manufacturing and supply chain and sales and marketing. Parts of our direct and indirect supply chain are in China, and are accordingly subject to disruption or product contamination. Additionally, our results of operations could be adversely affected to the extent that COVID-19 or any other epidemic harms our business or the economy in general either in China or in any other region in which we do business. For example, our customers may delay, cancel or redirect planned capital expenditures in order to focus resources on COVID-19 or in response to economic disruption related to COVID-19. The extent to which COVID-19 affected our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others, and could have an adverse effect on our business and financial condition.
Further, the U.S. federal government has called for, or enacted, substantial changes to healthcare, trade, fiscal, and tax policies, which may include changes to existing trade agreements and may have a significant impact on our operations. For example, the current administration has initiated the imposition of tariffs on certain foreign products, including from China, that have resulted in and may result in future retaliatory tariffs on U.S. goods and products. We cannot predict the impact, if any, that these changes could have on our business. If economic conditions worsen or new legislation is passed related to the healthcare system, trade, fiscal or tax policies, customer demand may not materialize to levels we require to achieve our anticipated financial results, which could have a material adverse effect on our business, financial condition and results of operations.
Uncertain credit markets and concerns regarding the availability of credit could impact consumer and customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers and creditors, including financial institutions. If the current situation continues to deteriorate or does not improve, our business could be negatively affected by factors such as reduced demand for our products resulting from a slow‑down or volatility in the general economy, supplier or customer disruptions and/or temporary interruptions in our ability to conduct day‑to‑day transactions through our financial intermediaries involving the payment to or collection of funds from our customers, vendors and suppliers.
The United Kingdom's withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business and operations.
In 2016 voters in the United Kingdom approved "Brexit," calling for the United Kingdom to withdraw from the European Union by March 29, 2019.(often referred to as “Brexit”). The effects of the Brexit vote and the perceptions as to the impact of the withdrawal of the U.K. exited from the European Union on January 31, 2020. Under the current withdrawal agreement between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December 31, 2020, during which European Union rules will continue to apply. The relationship between the United Kingdom and the European Union after the transition period has not been determined yet. As a result, the impact of Brexit is not yet known and depends on any
agreements the United Kingdom may adversely affect business activitymake to retain access to European Union or other markets after the transition period. The withdrawal could potentially disrupt the free movement of goods, services and economic and market conditions inpeople between the U.K., the Eurozone, and globally, and have contributed to instability in global financial and foreign exchange markets, including volatility in the value of the pound sterling and the euro.European Union, undermine bilateral cooperation in key geographic areas and significantly disrupt trade between the U.K. and the European Union or other nations as the U.K. pursues independent trade relations. In addition, Brexit could lead to additionallegal uncertainty and potentially divergent national laws and regulations as the U.K. determines which European Union laws to replace or replicate. Any of these events, along with any political, legaleconomic and regulatory changes that may occur, could cause political and economic instabilityuncertainty in the European Union.Europe and internationally and harm our business and financial results. Natus has not identified any additional risk factors under Brexit other than those discussed herein. Additionally, we have not identified any trends or potential changes to critical accounting estimates as a result of Brexit. WeBrexit at this time, however, we will continue to assess risk factorsthe potential impact of Brexit on our business and operations, and on accounting and reporting considerations. Any of theseThe effects of Brexit among others, could adversely affect our business, financial condition or future results.
Our operating results may suffer because of our exposure to foreign currency exchange rate fluctuations.
Substantially all of our sales contracts with our U.S. based customers provide for payment in U.S. dollars. With the exception of our Canadian operations, substantially all of the revenue and expenses of our foreign subsidiaries are denominated in the applicable foreign currency. Our exposure to the currency fluctuations is enhanced as a result of the Otometrics acquisition. To date we have executed only limited foreign currency contracts to hedge these currency risks. Our future revenue and expenses may be subject to volatility due to exchange rate fluctuations that could result in foreign exchange gains and
losses associated with foreign currency transactions and the translation of assets and liabilities denominated in foreign currencies.
Substantially all our sales from our U.S. operations to our international distributors provide for payment in U.S. dollars. A strengthening of the U.S. dollar relative to other foreign currencies could increase the effective cost of our products to our international distributors as their functional currency is typically not the U.S. dollar. This could have a potential adverse effect on our ability to increase or maintain average selling prices of our products to our foreign-based customers.
The interest rates on our revolving credit facility are priced using a spread over LIBOR.
LIBOR, the London interbank offered rate, is the basic rate of interest used in lending between banks on the London interbank market and is widely used as a reference for setting the interest rate on loans globally. We typically use LIBOR as a reference rate in our term loans such that the interest due to our creditors pursuant to a term loan extended to us is calculated using LIBOR. Most of our term loan agreements contain a stated minimum value for LIBOR.
If we fail in our efforts to educate clinicians, government agency personnel, and third-party payors about the effectiveness of our products, we may not achieve future sales growth.
It is critical to the success of our sales efforts that we educate a sufficient number of clinicians, hospital administrators, and government agencies about our products and the costs and benefits of their use. The commercial success of our products depends upon clinician, government agency, and other third-party payerpayor confidence in the economic and clinical benefits of our products as well as their comfort with the efficacy, reliability, sensitivity and specificity of our products. We believe that clinicians will not use our products unless they determine, based on published peer-reviewed journal articles and experience, that our products provide an accurate and cost-effective alternative to other means of testing or treatment. Our customers may choose to use competitive products, which may be less expensive or may provide faster results than our devices. Clinicians are traditionally slow to adopt new products, testing practices and clinical treatments, partly because of perceived liability risks and the uncertainty of third-party reimbursement. If clinicians, government agencies and hospital administrators do not adopt our products, we may not maintain profitability. Factors that may adversely affect the medical community’s acceptance of our products include:
Publication of clinical study results that demonstrate a lack of efficacy or cost-effectiveness of our products;
Changing governmental and physician group guidelines;
Actual or perceived performance, quality, price, and total cost of ownership deficiencies of our products relative to other competitive products;
Our ability to maintain and enhance our existing relationships and to form new relationships with leading physicians, physician organizations, hospitals, state laboratory personnel, and third-party payers;payors;
Changes in federal, state and third-party payerpayor reimbursement policies for our products; and
Repeal of laws requiring universal newborn hearing screening and metabolic screening.
Sales throughto members under group purchasing organizationsagreements and sales to high volume purchasers may reduce our average selling prices, which could reduce our operating margins.
We have entered and expect in the future to enter into agreements with customers who purchase a high volume of our products. Our agreements with these customers may contain discounts from our normal selling prices and other special pricing considerations, which could cause our operating margins to decline. In addition, we have entered into agreements to sell our products to members of GPOs, which negotiate volume purchase prices for medical devices and supplies for member hospitals,
group practices and other clinics. While we make sales directly to GPO members, the GPO members receive volume discounts from our normal selling price and may receive other special pricing considerations from us. Sales to members of all GPOs accounted for approximately 13.3%18.7%, 14.5%13.3% and 12.3%14.5% of our total revenue during 2019, 2018 2017 and 2016,2017, respectively. Certain other existing customers may be members of GPOs with which we do not have agreements. Our sales efforts through GPOs may conflict with our direct sales efforts to our existing customers. If we enter into agreements with new GPOs and some of our existing customers begin purchasing our products through those GPOs, our operating margins could decline.
Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.
Many healthcare industry companies, includeincluding our customers and competitors, are consolidating to create new companies with greater market power. As the healthcare industry consolidates, competition to provide goods and services to our customers could become more intense. Our customers may try to use their market power to negotiate price concessions and our competitors may utilize their size and broad product lines to offer cheaper alternatives to our products. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues would decrease and our consolidated earnings, financial condition, or cash flow would suffer.
Demand for some of our products depends on the capital spending policies of our customers, and changes in these policies could harm our business.
A majority of customers for our products are hospitals, physician offices, and clinics. Many factors, including public policy spending provisions, available resources, and economic cycles have a significant effect on the capital spending policies of these entities and therefore the amount that they can spend on our equipment products. If budget resources limit the capital spending of our customers, they will be unlikely to either purchase any new equipment from us or upgrade to any of our newer equipment products. Lack of liquidity in credit markets and uncertainty about future economic conditions can have an adverse effect on the spending patterns of our customers. These factors can have a significant adverse effect on the demand for our products.
Our markets are very competitive and in the United States we sell certain of our products in a mature market.
We face competition from other companies in all of our product lines. Our competitors range from small privately held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.
The markets for certain of our products in the U.S.,United States, including the newborn hearing screening and EEG monitoring markets, are mature and we are unlikely to see significant growth for such products in the U.S.United States. The market for newborn care products is affected by birthrates, and a declining U.S. birthrate has adversely affected our operating results in recent periods. In the U.S.United States we derive a significant portion of our revenue from the sale of disposable supplies that are used with our hearing screening devices.supplies. Our hearing disposable supply products could face increasing competition, including competitors offering lower prices, which could have an adverse effect on our revenue and margins.
Our competitors may have certain competitive advantages, which include the ability to devote greater resources to the development, promotion, and sale of their products. Consequently, we may need to increase our efforts, and related expenses for research and development, marketing, and selling to maintain or improve our position.
We expect recurring sales to our existing customers to generate a majority of our revenue in the future, and if our existing customers do not continue to purchase products from us, our revenue may decline.
Our balance sheet includes significant intangible assets, including goodwill and other acquired intangible assets. The determination of related estimated useful lives and whether these assets are impaired involves significant judgment. Our ability to accurately predict future cash flows related to these intangible assets might be hindered by events over which we completedhave no control. Due to the acquisitionhighly competitive nature of the medical device industry, new technologies could impair the value of our neurosurgery businessintangible assets if they create market conditions that adversely affect the competitiveness of our products. Further, declines in our market capitalization may be an indicator that our intangible assets or goodwill carrying values exceed their fair values which could lead
to potential impairment charges that could impact our operating results. In the past we have recorded charges for goodwill impairment and impairments of our trade names.
If healthcare providers are not adequately reimbursed for procedures conducted with our devices or supplies, or if reimbursement policies change adversely, we may not be successful marketing and selling our products or technologies.
Clinicians, hospitals, and government agencies are unlikely to purchase our products if they are not adequately reimbursed for the procedures conducted with our devices or supplies. Unless a sufficient amount of conclusive, peer-reviewed clinical data about our products has been published, third-party payors, including insurance companies and government agencies, may refuse to provide reimbursement. Furthermore, even if reimbursement is provided, it may not be adequate to fully compensate the clinicians or hospitals. Some third-party payors may impose restrictions on the procedures for which they will provide reimbursement. If healthcare providers cannot obtain sufficient reimbursement from Integra LifeSciences.third-party payors for our products or the screenings conducted with our products, we may not achieve significant market acceptance of our products. Acceptance of our products in international markets will depend upon the availability of adequate reimbursement or funding within prevailing healthcare payment systems. Reimbursement, funding, and healthcare payment systems vary significantly by country. We may not obtain approvals for reimbursement in a timely manner or at all.
Adverse changes in reimbursement policies in general could harm our business. We are relyingunable to predict changes in the reimbursement methods used by third-party healthcare payors, particularly those in countries and regions outside the United States. For example, some payors are moving toward a managed care system in which providers contract to provide comprehensive healthcare for a fixed cost per person. In a managed care system, the cost of our products may not be incorporated into the overall payment for patient care or there may not be adequate reimbursement for our products separate from reimbursement for other procedures.
Because we rely on Integra LifeSciencesdistributors or sub-distributors to sell our products in most of our markets outside of the United States, our revenue could decline if our existing distributors reduce the volume of purchases from us, or if our relationship with any of these distributors is terminated.
We currently rely on our distributors or sub-distributors for a majority of our sales outside the United States. Some distributors also assist us with regulatory approvals and education of clinicians and government agencies. Our contracts with our distributors or sub-distributors do not assure us significant minimum purchase volume. If a contract with a distributor or sub-distributor is terminated for cause or by us for convenience, the distributor or sub-distributor will have no obligation to purchase products from us. We intend to continue our efforts to increase our sales in Europe, Japan, and other developed markets. If we fail to sell our products through our international distributors, we would experience a decline in revenue unless we begin to sell our products directly in those markets. We cannot be certain transition servicesthat we will be able to attract new international distributors to market our products effectively or provide timely and cost-effective customer support and service. Even if we are successful in selling our products through new distributors, the acquiredrate of growth of our revenue could be harmed if our existing distributors do not continue to sell a large dollar volume of our products. None of our existing distributors are obligated to continue selling our products.
We may be subject to foreign laws governing our relationships with our international distributors. These laws may require us to make payments to our distributors if we terminate our relationship for any reason, including for cause. Some countries require termination payments under local law or legislation that may supersede our contractual relationship with the distributor. Any required payments would adversely affect our operating results.
We are subject to a variety of operational risks inherent in our business which may disrupt our business and negatively impact our results of operations.
We are exposed to many types of operational risks, including business continuity, direct or indirect loss resulting from inadequate or failed internal and external processes, systems or human error, the effects of natural or man-made catastrophic events (such as natural disasters, pandemics, cyber-attacks, acts of terrorism, civil unrest and other catastrophes) or from other external events. For example, we conduct a significant portion of our activities, including administration and data processing, at the same time we are competing with themfacilities located in California which has experienced major earthquakes in the salepast, as well as other natural disasters. In addition, the ongoing outbreak of neurosurgery products. Integra LifeSciencesCOVID-19 since December 2019 has resulted in increased travel restrictions and extended shutdown of certain businesses in the region, as well as reports of dramatically reduced economic activity in the region, which may face conflicting interestsnegatively affect our operation particularly in performing required services for usAsia. Exposure to such events could disrupt our systems and thisoperations significantly, which may result in adverse effectsfinancial loss and reputational damage.
If we lose our relationship with any supplier of key product components or our relationship with a supplier deteriorates or key components are not available in sufficient quantities, our manufacturing could be delayed and our business could suffer.
We contract with third parties for the supply of some of the components used in our products and the production of our disposable products. Some of our suppliers are not obligated to continue to supply us. We have relatively few sources of supply for some of the components used in our products and in some cases we rely entirely on sole-source suppliers. In addition, the acquired business.lead-time involved in the manufacturing of some of these components can be lengthy and unpredictable. If our suppliers become
unwilling or unable to supply us with components meeting our requirements, it might be difficult to establish additional or replacement suppliers in a timely manner, or at all. This would cause our product sales to be disrupted and our revenue and operating results to suffer.
Replacement or alternative sources might not be readily obtainable due to regulatory requirements and other factors applicable to our manufacturing operations. Incorporation of components from a new supplier into our products may require a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product sales. This process may take a substantial period of time, and we may not be able to obtain the necessary regulatory clearance or approval. This could create supply disruptions that would harm our product sales and operating results.
We have substantial international operations which are subject to numerous risks; if our international operations are not successful, our business will be adversely affected.
In 2018,2019, approximately 43.3%41.0% of our sales were made outside the U.S.United States. We plan to expand our international sales and marketing efforts to increase sales of our products in foreign countries. We may not realize corresponding growth in revenue from growth in international unit sales, due to the lower average selling prices we receive on sales outside of the U.S.United States. Even if we are able to successfully expand our international selling efforts, we cannot be certain that we will be able to create or increase demand for our products outside of the U.S.United States. Our international operations are subject to other risks, which include:
Impact of possible recessions in economies outside the U.S.;United States;
Political and economic instability, including instability related to war and terrorist attacks and to political and diplomatic matters such as the BREXIT of the United Kingdom from the European Union;Brexit;
Adverse changes in tariffs and trade protection measures;
Difficulty in obtaining and maintaining foreign regulatory approval and complying with foreign regulations, including the EU Medical Device Regulation;
An outbreak of a contagious disease, such as COVID-19, which may cause us or our distributors, vendors and/or customers to temporarily suspend our or their respective operations in the affected city or country;
Contractual provisions governed by foreign law, such as local law rights to sales commissions by terminated distributors;
Decreased healthcare spending by foreign governments that would reduce international demand for our products;
Strengthening of the U.S. dollar relative to foreign currencies that could make our products less competitive because approximately half of our international sales are denominated in U.S. dollars;
Changes in capital and exchange controls affecting international trade;
Greater difficulty in accounts receivable collection and longer collection periods;
Difficulties of staffing and managing foreign operations;
Reduced protection for intellectual property rights in some countries and potentially conflicting intellectual property rights of third parties under the laws of various foreign jurisdictions;
Attitudes by clinicians, and cost reimbursement policies, towards use of disposable supplies that are potentially unfavorable to our business;
Complying with U.S. regulations that apply to international operations, including trade laws, the U.S. Foreign Corrupt Practices Act, and anti-boycott laws, as well as international laws such as the U.K. Bribery Act;
Loss of business through government tenders that are held annually in many cases; and
Potentially negative consequences from changes in tax laws, including legislative changes concerning taxation of income earned outside of the U.S.United States.
In particular, our international sales could be adversely affected by a strengthening of the U.S. dollar relative to other foreign currencies, which makes our products more costly to international customers for sales denominated in U.S. dollars.
We depend upon key employees in a competitive market for skilled personnel, and, without additional employees, we cannot grow or maintain profitability.
Our products and technologies are complex, and we depend substantially on the continued service of our senior management team. The loss of any of our key employees could adversely affect our business and slow our product development process. The successful implementation of our "One Natus" organizational structure also depends on key employees. Our future success will depend, in part, on the continued service of our key management personnel, software engineers, and other research and development employees, and our ability to identify, hire, and retain additional personnel, including customer service, marketing, and sales staff. Demand for these skilled employees in our industry is very competitive due to the limited number of people available with the necessary technical skills and understanding of our product technologies. We may be unable to attract and retain personnel necessary for the development of our business.
We have experienced seasonality in the sale of our products.
We experience seasonality in our revenue. For example, our sales typically decline from the second half of our fiscal year to the first half of the fiscal year, due to patterns in the capital budgeting and purchasing cycles of our customers, many of which
are government agencies, and the compensation arrangements of our direct sales employees, as those arrangements are tied to calendar-year sales plans. We anticipate that we will continue to experience seasonal fluctuations, which may lead to fluctuations in our quarterly operating results. We believe that you should not rely on our results of operations for interim periods as an indication of our expected results in any future period.
We have initiated changes to our information systems that could disrupt our business and our financial results.
We plan to continuously improve our information systems to support the form, functionality, and scale of our business. These types of transitions frequently prove disruptive to the underlying business of an enterprise and may cause us to incur higher costs than we anticipate. Failure to manage a smooth transition to the new systems and the ongoing operations and support of the new systems could materially harm our business operations.
Risks Related to Our Compliance and Regulatory Environment
Our ability to market and sell products depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations. Our failure to obtain or maintain regulatory approvals and compliance could negatively affect our business.
Our products and manufacturing operations are subject to extensive regulation in the United States by the FDA and by similar regulatory agencies in other countries. Our products are classified as medical devices. Medical devices are subject to extensive regulation by the FDA pursuant to regulations that are wide ranging and govern, among other things: design and development; manufacturing and testing; labeling; storage and record keeping; advertising, promotion, marketing, sales distribution and export; and surveillance and reporting of deaths or serious injuries.
Unless an exemption applies, each medical device that we propose to market in the U.S.United States must first receive one of the following types of FDA premarket review authorizations:
Clearance via Section 510(k) of the Food, Drug, and Cosmetics Act of 1938, as amended; or
Premarket approval via Section 515 of the Food, Drug, and Cosmetics Act if the FDA has determined that the medical device in question poses a greater risk of injury.
The FDA will clear marketing of a medical device through the 510(k) process if it is demonstrated that the new product is substantially equivalent to other 510(k)-cleared products. The premarket approval application process is much more costly, lengthy and uncertain than the 510(k) process, and must be supported by extensive data from preclinical studies and human clinical trials. The FDA may not grant either 510(k) clearance or premarket approval for any product we propose to market. Further, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a premarket approval application. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. If the FDA requires us to seek 510(k) clearance or premarket approval for modification of a previously cleared product for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease
marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective.
Delays in receipt of, or failure to receive, clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could adversely impact our operating results. If the FDA finds that we have failed to comply with these requirements, the FDA can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such as:
Fines, injunctions and civil penalties;
Recall or seizure of our products;
Issuance of public notices or warnings;
Imposition of operating restrictions, partial suspension, or total shutdown of production;
Refusal of our requests for Section 510(k) clearance or premarket approval of new products;
Withdrawal of Section 510(k) clearance or premarket approvals already granted;
Criminal prosecution;
Domestic regulation of our products and manufacturing operations, other than that which is administered by the FDA, includes the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these Acts; or
Foreign governments and regulatory authorities have, and may continue to, propose and implement regulations that apply to our products and operations. For example, in 2017 the European Union adopted the EU Medical Device Regulation, which imposes stricter requirements for the marketing and sale of medical devices, including new quality system and post-market surveillance requirements once it is fully implemented in 2020. Penalties for regulatory non-compliance could be severe, including
fines and revocation or suspension of a company's business license, mandatory price reductions, and criminal sanctions. Future laws and regulations may have a material adverse effect on our business.
Our business would be harmed if the FDA determines that we have failed to comply with applicable regulations governing the manufacture of our products and/or we do not pass an inspection.
We and our suppliers are required to demonstrate and maintain compliance with the FDA’s Quality System Regulation. The Quality System Regulation sets forth the FDA’s requirements for good manufacturing practices of medical devices and includes requirements for, among other things, the design, testing, production processes, controls, quality assurance, labeling, packaging, storage and shipping of such products. In addition, we and our suppliers must engage in extensive recordkeeping and reporting and must make available our manufacturing facility and records for periodic unscheduled inspections by federal, state and foreign agencies, including the FDA. We cannot assure you that we and our suppliers are or will continue to be in full compliance with the Quality System Regulation, nor that we will not encounter any manufacturing difficulties.
In 2014 and 2016 we received formal communications from the FDA regarding deficiencies in our manufacturing processes in our Seattle facility. As a result, we imposed ship-holds on certain of our products produced there and have discontinued certain other products produced in that facility. We are dedicating substantial resources to the resolution of the conditions identified by the FDA. These actions had an adverse effect on our results of operations in 2016 and 2017.
Our inability to address issues that have been raised by the FDA, or failure of us or our third party suppliers and manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including, among other things, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, seizures or recalls of products and manufacturing restrictions, any of which could harm our business.
Our business may suffer if we are required to revise our labeling or promotional materials, or if the FDA takes an enforcement action against us for off-label uses.
We are prohibited by the FDA from promoting or advertising our medical device products for uses not within the scope of our clearances or approvals, or from making unsupported promotional claims about the benefits of our products. If the FDA determines that our claims are outside the scope of our clearances, or are unsupported, it could require us to revise our promotional claims or take enforcement action against us. If we were subject to such an action by the FDA, our sales could be delayed, our revenue could decline, and our reputation among clinicians could be harmed. Likewise, if we acquire new products, either through the purchase of products, technology assets, or businesses, that are subsequently deemed to have inadequate supporting data, we may be required to (i) obtain adequate data, which could be costly and impede our ability to market these products, or (ii) modify the labeling on these products, which could impair their marketability, as described above.
We are subject to data privacy laws and our failure to comply with them may require us to make significant changes to our products or incur penalties or other liabilities.
Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including personally identifiable information (“PII”), personal health information, financial information, intellectual property and other sensitive information related to our customers and workforce. The collection, maintenance, protection, use, transmission, disclosure and disposal of certain personal information and the security of medical devices are regulated at the U.S. federal and state, international and industry levels. U.S. federal and state laws, such as the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information. We sign business associate agreements with certain customers for which we perform services as business associates under HIPAA, and therefore we are directly subject to certain provisions of HIPAA that are applicable to business associates. Noncompliance with laws and regulations relating to privacy and security of personal information, including HIPAA, or with contractual obligations under any business associate agreement may lead to significant fines, civil and criminal penalties, or liabilities. We also may be required to report breaches of protected health information that we experience. The U.S. Department of Health and Human Services (“HHS”), audits the compliance of business associates and enforces HIPAA privacy and security standards. HHS enforcement activity has become more significant over the last few years and HHS has signaled its intent to continue this trend.
In addition to the regulation of personal health information, a number of states have also adopted laws and regulations that may affect our privacy and data security practices for other kinds of PII, such as state laws that govern the use, disclosure and protection of personal information, such as social security numbers, or that are designed to protect credit card account data. State consumer protection laws, including the California Consumer Privacy Act of 2018 (“CCPA”), which became effective on January 1, 2020, may also establish privacy and security standards for use and management of PII, including information related to customers, suppliers and care providers. The CCPA provides individuals certain rights regarding the collection or processing of personal data related to California residents, which may restrict our ability to use personal data, of California residents. Failure to comply with the CCPA could result in penalties of up to $7,500 per violation.
Outside the United States, we are impacted by the privacy and data security requirements at the international, national and regional level, and on an industry specific basis. We serve customers across the globe. Legal requirements in these countries relating to the collection, storage, handling and transfer of personal data and potentially intellectual property continue to evolve with increasingly strict enforcement regimes. More privacy and security laws and regulations are being adopted, and more are be enforced, with potential for significant financial penalties. In the European Union, increasingly stringent data protection and privacy rules that will have substantial impact on the use of patient data across the healthcare industry became effective in May 2018. The European Union General Data Protection Regulation (“GDPR”) applies uniformly across the European Union and to businesses in other countries that target European Union residents and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR also requires companies processing personal data of individuals, including employees, residing in the European Union to comply with European Union privacy and data protection rules. Other international jurisdictions, have issued privacy laws that mirror many of the requirements of GDPR. As we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple data privacy laws. Failure to comply with these laws may result in significant fines and other administrative penalties and harm our business.
Compliance with these laws and regulations may require significant additional costs or changes in our business, which could adversely affect our results of operations or financial condition. Noncompliance with these laws and regulations could result in the imposition of fines and penalties or could result in significant civil and other liabilities. Additionally, the restrictions imposed by these laws and regulations may limit the use and adoption of our products, reduce overall demand for our products, require us to modify our data handling practices and impose additional costs and burdens.
An interruption in or breach of security of our information or manufacturing systems, including the occurrence of a cyber-incident or a vulnerability in our cybersecurity, or disclosure of private patient health information, may result in a loss of business or damage to our reputation.
We rely on communications, information and manufacturing systems to conduct our business. Any failure, interruption or cyber incident affecting these systems could result in failures or disruptions in our customer relationship management or product manufacturing. Similarly, there can be no assurance that our third-party collaborators, distributors and other contractors and consultants will be successful in protecting our data that is stored on their systems. A cyber incident is an intentional attack or an unintentional event that can include an unauthorized actor gaining access to our systems to disrupt operations, corrupt data, or steal confidential information. The occurrence of any failures, interruptions or cyber incidents could result in a loss of customer business or reputation and have a material effect on our business, financial condition, results of operations and cash flows. In addition, our products are used in customer networks transmitting a range of sensitive information and any actual or perceived exposure of our products used in customer networks to malicious software or cyber-attacks could adversely affect our business and results of operations.
In the course of performing our business we obtain, from time to time, confidential patient health information. For example, we may learn patient names and be exposed to confidential patient health information when we provide training on our products to our customers’ staff. Complying with federal and state privacy and security requirements imposes compliance related costs, subjects us to potential regulatory audits, and may restrict our business operations. These various laws may be subject to varying interpretations by courts and government agencies creating potentially complex compliance issues for our business. If we were to violate any of our legal obligations to safeguard any confidential patient health information or protected health information against improper use and disclosure, we could lose customers and be exposed to liability, and our reputation and business could be harmed. Concerns or allegations about our practices with regard to the privacy or security of personal health information or other privacy-related matters, even if unfounded, could damage our reputation and harm our business.
We are also subject to new U.S. laws as well as laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than previous corresponding U.S. laws. These laws and regulations impose technical and organizational measures to ensure the security of personal data and may require that we notify regulatory agencies, individuals or the public about any data security breaches. In particular, in the United States, the newly passed CCPA imposes a private right of action with damages of up to $750 per person in the event of certain data breaches. Other states are considering similar laws. As these laws and regulations develop in the United States and we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple cybersecurity laws. Failure to comply with these laws may result in significant fines and other administrative penalties and harm our business, and could expose us to significant civil damages.
The FDA has issued guidance advising manufacturers to take cybersecurity risks into account in product design for connected medical devices and systems, to assure that appropriate safeguards are in place to reduce the risk of unauthorized access or modification to medical devices that contain software and reduce the risk of introducing threats into hospital systems that are connected to such devices. The FDA also issued guidance on post market management of cyber security in medical devices. Compliance with these requirements may require changes in business practices, complicate our operations, and add complexity and additional management and oversight needs. They also may complicate our clinical research activities, as well as product
offerings that involve transmission or use of clinical data. Failure to comply with these laws could result in vulnerabilities that would make us susceptible to hackers and other cyber attacks, as well as fines or administrative penalties that, if imposed, would harm our business.
Healthcare reforms, changes in healthcare policies, and changes to third-party reimbursements for our products may affect demand for our products.
Uncertainty in the U.S. healthcare system may influence the way our customers spend on medical devices, supplies, and services in the future. The U.S. Patient Protection and Affordable Care Act and the Healthcare and Education Reconciliation Act of 2010 (“ACA”) may be modified, repealed, or otherwise invalidated, in whole or in part. Future rulemakings could affect rebates, prices, or the rate of price increase for healthcare products and services. Cost-containing measures implemented by healthcare providers worldwide could harm our profitability. If we fail to effectively react to healthcare reforms, our business may be adversely affected.
Regulations related to “conflict minerals” may force us to incur additional expenses, may result in damage to our business reputation and may adversely impact our ability to conduct our business.
The Dodd‑Frank Wall Street Reform and Consumer Protection Act and the rules promulgated by the SEC thereunder require companies, including Natus, to disclose the existence in their products of certain metals, known as “conflict minerals,” which are metals mined from the Democratic Republic of the Congo and adjoining countries. These rules requires investigative efforts, which has and will continue to cause us to incur associated costs, could adversely affect the sourcing, availability and pricing of minerals used in our products and may cause reputational harm if we determine that certain of our components contain such conflict minerals or if we are unable to alter our processes or sources of supply to avoid using such materials, all of which could adversely impact sales of our products and results of operations.
Risks Related to our Intellectual Property and Potential Litigation
We may not be able to preserve the value of our intellectual property because we may not be able to protect access to it or we may lose our intellectual property rights due to expiration of our licenses or patents.
If we fail to protect our intellectual property rights or if our intellectual property rights do not adequately cover the technology we employ, other medical device companies could sell products with features similar to ours, and this could reduce demand for our products. We protect our intellectual property through a combination of patent, copyright, trade secret and trademark laws. Despite our efforts to protect our proprietary rights, others may attempt to copy or otherwise improperly obtain and use our products or technology. Policing unauthorized use of our technology is difficult and expensive, and we cannot be certain that the steps we have taken will prevent misappropriation. Our means of protecting our proprietary rights may be inadequate. Enforcing our intellectual property rights could be costly and time consuming and may divert our management’s attention and resources. Failing to enforce our intellectual property rights could also result in the loss of those rights.
U.S. tax reform legislation could materially affect our business and financial condition.
The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law in December 2017. The new law made numerous changes to federal corporate tax law that we expect will impact our effective tax rate in future periods. The changes included in the Tax Act were broad and complex and included, among others, reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limiting the tax deduction for interest expense to 30% of adjusted earnings, eliminating net operating loss carrybacks, imposing a one-time tax on offshore earnings at reduced rates regardless of whether they are repatriated, allowing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. The final impacts of the Tax Act may differ from our current estimates, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates we have utilized to calculate the transition impacts.
If guidelines mandating universal newborn hearing screening do not continue to develop in foreign countries and governments do not mandate testing of all newborns as we anticipate, or if those guidelines have a long phase-in period, our sales of newborn hearing screening products may not achieve the revenue growth we have achieved in the past.
We estimate that approximately 95% of the children born in the United States are currently being tested for hearing impairment prior to discharge from the hospital. To date, there has been only limited adoption of newborn hearing screening prior to hospital discharge by foreign governments, and when newborn hearing screening programs are enacted by foreign governments there can be a phase-in period spanning several years. The widespread adoption of guidelines depends, in part, on our ability to educate foreign government agencies, neonatologists, pediatricians, third-party payors, and hospital administrators about the benefits of universal newborn hearing screening as well as the use of our products to perform the screening and monitoring. Our revenue from our newborn hearing screening product lines may not grow if foreign governments do not require universal newborn
hearing screening prior to hospital discharge, if physicians or hospitals are slow to comply with those guidelines, or if governments provide for a lengthy phase-in period for compliance.
If we deliver products with defects, we may incur costs to repair and, possibly, recall that product and market acceptance of our products may decrease.
The manufacturing and marketing of our products involve an inherent risk of our delivering a defective product or products that do not otherwise perform as we expect. We may incur substantial expense to repair any such products and may determine to recall such a product, even if not required to do so under applicable regulations. Any such recall would be time consuming and expensive. Product defects or recalls may adversely affect our customers’ acceptance of the recalled and other of our products.
If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
We could be subject to healthcare fraud regulation and enforcement by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: (i) the federal healthcare programs Anti-Kickback Law, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare or Medicaid, (ii) federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers, and/or (iii) state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any
third-party payor, including commercial insurers, many of which differ from their federal counterparts in significant ways, thus complicating compliance efforts.
If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
Our operating results would suffer if we were subject to a protracted infringement claim.
The medical technology industry is characterized by a substantial amount of litigation and related administrative proceedings regarding patents and intellectual property rights. We expect that medical screening and diagnostic products may become increasingly subject to third-party infringement claims as the number of competitors in our industry grows and the functionality of products overlap. Third parties such as individuals, educational institutions, or other medical device companies may claim that we infringe their intellectual property rights. Any claims, with or without merit, could have any of the following negative consequences:
Result in costly litigation and damage awards;
Divert our management’s attention and resources;
Cause product shipment delays or suspensions; or
Require us to seek to enter into royalty or licensing agreements.
We are currently subject to cases based on third-party patent infringement claims. A successful claim of infringement against us from any current or future claim could result in a substantial damage award and materially harm our financial condition. Our failure or inability to license the infringed or similar technology, or design and build non-infringing products, could prevent us from selling our products and adversely affect our business and financial results.
We may also find it necessary to bring infringement actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and disruptive of our management’s attention, and in any event may not lead to a successful result relative to the resources dedicated to any such litigation.
We license intellectual property rights from third parties and would be adversely affected if our licensors do not appropriately defend their proprietary rights or if we breach any of the agreements under which we license commercialization rights to products or technology from others.
We license rights from third parties for products and technology that are important to our business. If our licensors are unsuccessful in asserting and defending their proprietary rights, including patent rights and trade secrets, we may lose the competitive advantages we have through selling products that we license from third parties. Additionally, if it is found that our licensors infringe on the proprietary rights of others, we may be prohibited from marketing our existing products that incorporate
those proprietary rights. Under our licenses, we are subject to commercialization and development, sublicensing, royalty, insurance and other obligations. If we fail to comply with any of these requirements, or otherwise breach a license agreement, the licensor may have the right to terminate the license in whole or to terminate the exclusive nature of the license.
Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages, and an increase in our insurance rates.
The sale and use of our products could lead to the filing of a product liability claim by someone claiming to have been injured using one of our products or claiming that one of our products failed to perform properly. We are currently subject to one such lawsuit. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business reputation or financial condition. Our product liability insurance may not protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future.
Our stock price may be volatile, which may cause the value of our stock to decline or subject us to a securities class action litigation.
The trading price of our common stock price may be volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:
general economic, industry and market conditions;
actions by institutional or other large stockholders;
the depth and liquidity of the market for our common stock;
volume and timing of orders for our products;
developments generally affecting medical device companies;
the announcement of new products or product enhancements by us or our competitors;
changes in earnings estimates or recommendations by securities analysts;
investor perceptions of us and our business, including changes in market valuations of medical device companies; and
our results of operations and financial performance.
In addition, the stock market in general, and the NASDAQNasdaq Stock Market and the market for medical devices in particular, have experienced substantial price and volume volatility that is often seemingly unrelated to the operating performance of particular companies. These broad market fluctuations may cause the trading price of our common stock to decline. In the past, securities class action litigation has often been brought against a company after a period of volatility in the market price of its common stock. We may become involved in this type of litigation in the future. Any securities litigation claims brought against us could result in substantial expense and the diversion of management’s attention from our business.
ITEM 1B. Unresolved Staff Comments.
None.
ITEM 2. Properties
Our corporate headquarters areis located in Pleasanton, California, in a facility covering 8,200 square feet pursuant to a lease that expires in October 2019.January 2025.
We also utilize the following properties:
Company-owned Facilities:
44,900 square feet in Oakville, Ontario, Canada, primarily utilized substantially for research and development;
6,400 square feet in Old Woking, England, utilized substantially for research and development.
Leased Facilities:
Following is a listing of our most significant leased properties; we have a number of smaller facilities under lease in various countries where we operate.
124,000 square feet in Middleton, Wisconsin, pursuant to a lease that expires in April 2024, that is primarily utilized for manufacturing;manufacturing, technical support, customer service, marketing and research and development;
65,000 square feet in Seattle, Washington, pursuant to a lease that expires in December 2020, that is utilized substantially for manufacturing;
52,000 square feet in Taastrup, Denmark, pursuant to a lease with the option to terminate with six months-notice beginning January 2022, that is utilized for manufacturing, research and development, marketing and sales, and general and administrative;
ITEM 3. Legal Proceedings
We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. We are not currently involved in any legal or administrative proceedings that we believe are likely to have a material effect on our business, financial condition, or results of operations, although we cannot be assured of the outcome of such matters.
ITEM 4. Mine Safety Disclosures
The disclosure required by this item is not applicable.
PART II
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock trades on the Nasdaq Global Select Market under the symbol “BABY”“NTUS”. The following table sets forth, for the periods indicated, the high and low sale price per share of our common stock, as reported on the Nasdaq Global Select Market.
| High | Low | High | Low | |||||||||||
| Fiscal Year Ended December 31, 2019: | ||||||||||||||
| Fourth Quarter | $ | 34.89 | $ | 29.67 | ||||||||||
| Third Quarter | 32.85 | 22.25 | ||||||||||||
| Second Quarter | 27.90 | 23.54 | ||||||||||||
| First Quarter | 34.63 | 24.88 | ||||||||||||
| Fiscal Year Ended December 31, 2018: | ||||||||||||||
| Fourth Quarter | $ | 36.85 | $ | 27.69 | $ | 36.85 | $ | 27.69 | ||||||
| Third Quarter | 37.90 | 31.05 | 37.90 | 31.05 | ||||||||||
| Second Quarter | 37.95 | 31.10 | 37.95 | 31.10 | ||||||||||
| First Quarter | 39.25 | 28.00 | 39.25 | 28.00 | ||||||||||
| Fiscal Year Ended December 31, 2017: | ||||||||||||||
| Fourth Quarter | $ | 43.60 | $ | 37.10 | ||||||||||
| Third Quarter | 39.50 | 31.65 | ||||||||||||
| Second Quarter | 41.25 | 33.28 | ||||||||||||
| First Quarter | 39.75 | 33.55 | ||||||||||||
As of February 20, 2019,24, 2020, there were 33,777,38834,105,116 shares of our common stock issued and outstanding and held by approximately 105101 stockholders of record. We estimate that there are approximately 18,75814,518 beneficial owners of our common stock.
In December 2019, the Board of Directors approved a share repurchase program, which authorized the repurchase from time to time of up to a maximum of $50 million of our outstanding common stock. The program is scheduled to expire on December 12, 2021. No shares have been repurchased as of February 28, 2020.
Dividends
We have never declared or paid cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future.
Stock Performance Graph
The following information of Part II Item 5 is being furnished and shall not be deemed to be “soliciting material” or to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section, nor will it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference thereto.
The following graph shows a comparison, from January 1, 20142015 through December 31, 2018,2019, of cumulative total return for our common stock, the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index assumes reinvestment of dividends.
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |||||||||||||||||||||||||||||
| Natus Medical Inc. | Return % | 60.18 | 33.32 | (27.58 | ) | 9.77 | (10.90 | ) | Return % | 33.32 | (27.58 | ) | 9.77 | (10.92 | ) | (3.06 | ) | |||||||||||||||||||||||
| Cum $ | 100.00 | 160.18 | 213.56 | 154.67 | 169.78 | 151.24 | Cum $ | 100.00 | 133.32 | 96.56 | 105.99 | 94.42 | 91.53 | |||||||||||||||||||||||||||
| NASDAQ Composite-Total Returns | Return % | 14.75 | 6.96 | 8.87 | 29.64 | (2.84 | ) | Return % | 6.96 | 8.87 | 29.64 | (2.84 | ) | 36.69 | ||||||||||||||||||||||||||
| Cum $ | 100.00 | 114.75 | 122.74 | 133.62 | 173.22 | 168.30 | Cum $ | 100.00 | 106.96 | 116.45 | 150.96 | 146.67 | 200.49 | |||||||||||||||||||||||||||
| S&P 500 Health Care Equipment Index | Return % | 26.28 | 5.97 | 6.48 | 30.90 | 16.24 | Return % | 5.97 | 6.48 | 30.90 | 16.24 | 29.32 | ||||||||||||||||||||||||||||
| Cum $ | 100.00 | 126.28 | 133.82 | 142.50 | 186.53 | 216.82 | Cum $ | 100.00 | 105.97 | 112.85 | 147.71 | 171.70 | 222.04 | |||||||||||||||||||||||||||
Purchases of Equity Securities by the Issuer
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs | |||||||||
| February 1, 2018—February 28, 2018 | 29,722 | $ | 31.23 | 29,722 | $ | 29,071,782 | |||||||
| March 1, 2018—March 31, 2018 | 118,171 | $ | 32.19 | 147,893 | $ | 25,271,403 | |||||||
| June 1, 2018—June 30, 2018 | 25,652 | $ | 34.79 | 173,545 | $ | 24,378,970 | |||||||
| Total | 173,545 | $ | 32.41 | 173,545 | $ | 24,378,970 | |||||||
ITEM 6. Selected Financial Data
The following tables set forth certain selected consolidated financial data for each of the years in the five-year period ended December 31, 2018,2019, and is derived from the Consolidated Financial Statements of Natus Medical Incorporated and its subsidiaries. The Consolidated Financial Statements for each of the years in the three-year period ended December 31, 20182019 are included elsewhere in this report. The selected consolidated balance sheet data as of December 31, 2017, 2016 2015 and 20142015 and the consolidated statements of operations data for the years ended December 31, 20152016 and 20142015 are derived from our Consolidated Financial Statements, which are not included in this report. The selected consolidated financial data set forth below is qualified in its entirety by, and should be read in conjunction with, the Consolidated Financial Statements and Notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this report.
| Year ended December 31, | Year ended December 31, | |||||||||||||||||||||||||||||||||||||
| 2018 | 2017 | 2016 | 2015 | 2014 | 2019 | 2018 | 2017 | 2016 | 2015 | |||||||||||||||||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | |||||||||||||||||||||||||||||||||||||
| Consolidated Statement of Operations Data (a): | ||||||||||||||||||||||||||||||||||||||
| Consolidated Statement of Operations Data (a)(b): | Consolidated Statement of Operations Data (a)(b): | |||||||||||||||||||||||||||||||||||||
| Revenue | $ | 530,891 | $ | 500,970 | $ | 381,892 | $ | 375,865 | $ | 355,834 | $ | 495,175 | $ | 530,891 | $ | 500,970 | $ | 381,892 | $ | 375,865 | ||||||||||||||||||
| Cost of revenue | 217,952 | 213,376 | 144,632 | 145,492 | 138,480 | 196,551 | 217,952 | 213,376 | 144,632 | 145,492 | ||||||||||||||||||||||||||||
| Intangibles amortization | 8,924 | 6,380 | 2,327 | 2,836 | 2,967 | 6,916 | 8,924 | 6,380 | 2,327 | 2,836 | ||||||||||||||||||||||||||||
| Gross profit | 304,015 | 281,214 | 234,933 | 227,537 | 214,387 | 291,708 | 304,015 | 281,214 | 234,933 | 227,537 | ||||||||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||||||||
| Marketing and selling | 136,680 | 126,166 | 84,834 | 87,675 | 85,729 | 129,109 | 136,680 | 126,166 | 84,834 | 87,675 | ||||||||||||||||||||||||||||
| Research and development | 61,482 | 51,822 | 33,443 | 30,434 | 30,100 | 58,733 | 61,482 | 51,822 | 33,443 | 30,434 | ||||||||||||||||||||||||||||
| General and administrative | 70,599 | 74,424 | 50,877 | 46,363 | 45,444 | 59,649 | 70,599 | 74,424 | 50,877 | 46,363 | ||||||||||||||||||||||||||||
| Intangibles amortization | 22,585 | 19,171 | 8,983 | 7,447 | 3,025 | 15,144 | 22,585 | 19,171 | 8,983 | 7,447 | ||||||||||||||||||||||||||||
| Restructuring | 37,231 | 914 | 1,536 | 2,145 | 4,238 | 44,739 | 37,231 | 914 | 1,536 | 2,145 | ||||||||||||||||||||||||||||
| Total operating expense | 328,577 | 272,497 | 179,673 | 174,064 | 168,536 | 307,374 | 328,577 | 272,497 | 179,673 | 174,064 | ||||||||||||||||||||||||||||
| Income from operations | (24,562 | ) | 8,717 | 55,260 | 53,473 | 45,851 | (15,666 | ) | (24,562 | ) | 8,717 | 55,260 | 53,473 | |||||||||||||||||||||||||
| Other income (expense), net | (7,698 | ) | (3,567 | ) | (357 | ) | (1,064 | ) | 158 | |||||||||||||||||||||||||||||
| Income before provision for income tax | (32,260 | ) | 5,150 | 54,903 | 52,409 | 46,009 | ||||||||||||||||||||||||||||||||
| Provision for income tax | (9,325 | ) | 25,443 | 12,309 | 14,485 | 13,531 | ||||||||||||||||||||||||||||||||
| Other expense, net | (5,591 | ) | (7,698 | ) | (3,567 | ) | (357 | ) | (1,064 | ) | ||||||||||||||||||||||||||||
| Income (loss) before provision (benefit) for income tax | (21,257 | ) | (32,260 | ) | 5,150 | 54,903 | 52,409 | |||||||||||||||||||||||||||||||
| Provision (benefit) for income tax | (5,586 | ) | (9,325 | ) | 25,443 | 12,309 | 14,485 | |||||||||||||||||||||||||||||||
| Net income (loss) | $ | (22,935 | ) | $ | (20,293 | ) | $ | 42,594 | $ | 37,924 | $ | 32,478 | $ | (15,671 | ) | $ | (22,935 | ) | $ | (20,293 | ) | $ | 42,594 | $ | 37,924 | |||||||||||||
| Earnings per share: | ||||||||||||||||||||||||||||||||||||||
| Earnings (loss) per share: | ||||||||||||||||||||||||||||||||||||||
| Basic | $ | (0.69 | ) | $ | (0.62 | ) | $ | 1.31 | $ | 1.17 | $ | 1.03 | $ | (0.47 | ) | $ | (0.69 | ) | $ | (0.62 | ) | $ | 1.31 | $ | 1.17 | |||||||||||||
| Diluted | $ | (0.69 | ) | $ | (0.62 | ) | $ | 1.29 | $ | 1.14 | $ | 1.00 | $ | (0.47 | ) | $ | (0.69 | ) | $ | (0.62 | ) | $ | 1.29 | $ | 1.14 | |||||||||||||
| Weighted average shares used in the calculation of earnings per share: | ||||||||||||||||||||||||||||||||||||||
| Basic | 33,111 | 32,564 | 32,460 | 32,348 | 31,499 | 33,696 | 33,111 | 32,564 | 32,460 | 32,348 | ||||||||||||||||||||||||||||
| Diluted | 33,111 | 32,564 | 33,056 | 33,241 | 32,568 | 33,696 | 33,111 | 32,564 | 33,056 | 33,241 | ||||||||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||||||||||||||||
| 2018 | 2017 | 2016 | 2015 | 2014 | 2019 | 2018 | 2017 | 2016 | 2015 | |||||||||||||||||||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||||||||||||||||||||||||
| Consolidated Balance Sheet Data: | ||||||||||||||||||||||||||||||||||||||
| Cash, cash equivalents, and short-term investments | $ | 56,373 | $ | 88,950 | $ | 247,750 | $ | 82,469 | $ | 66,558 | $ | 63,297 | $ | 56,373 | $ | 88,950 | $ | 247,750 | $ | 82,469 | ||||||||||||||||||
| Working capital | 152,329 | 213,491 | 325,858 | 164,248 | 148,665 | 126,928 | 152,329 | 213,491 | 325,858 | 164,248 | ||||||||||||||||||||||||||||
| Total assets | 638,140 | 709,919 | 649,012 | 479,496 | 434,821 | 622,527 | 638,140 | 709,919 | 649,012 | 479,496 | ||||||||||||||||||||||||||||
| Long-term debt (including current portion) and short-term borrowings | 105,000 | 154,283 | 140,000 | — | — | 54,665 | 104,474 | 154,283 | 140,000 | — | ||||||||||||||||||||||||||||
| Total stockholders’ equity | 398,444 | 422,097 | 417,374 | 390,710 | 352,715 | 416,123 | 398,444 | 422,097 | 417,374 | 390,710 | ||||||||||||||||||||||||||||
| (a) | Results of operations and financial position of the businesses we have acquired are included from their acquisition dates as follows: |
| (b) | Results of operations and financial position of the businesses we have divested or exited are not included from their exited dates as follows: GND and Neurocom in January 2019, and Medix in April 2019. |
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and the accompanying footnotes. MD&A includes the following sections:
Business
Year 20182019 Overview
Our consolidated revenue increaseddecreased by $29.9$35.7 million for the year ended December 31, 20182019 compared to the year ended December 31, 2017.2018. This increasedecrease was driven by the additionexit of GND and Neurocom businesses, the sale of our NeurosurgeryMedix business organic growthin Argentina, the impact of product discontinuations in our Otometrics business unit, offset by a decline in Newborn Care driven by non-recurring orders from the prior yearmarket, and product line rationalization.ship holds within Newborn Care and Hearing & Balance markets.
Net loss was $15.7 million, or $0.47 per share in the year ended December 31, 2019, compared with net loss of $22.9 million, or $0.69 per share in the year ended December 31, 2018, compared with net loss of $20.3 million, or $0.62 per diluted share in 2017.prior year. This decreaseincrease in income was primarily the result of restructuring expenses of $37.2 million incurred in 2018 related to costs associated with the Company's executive management transition and goodwill impairment charge related to our GND business. These restructuring expenses were offset by a reduction in tax expense in 2018 of $34.7 million compared to 2017. The reduction in tax expense was driven by our restructuring initiative announced in 2019. While we experienced a one-time tax costnet loss driven by our reorganization efforts, we generated cash flow from operations of $20.5 million in 2017 relating to the transition tax on the deemed repatriation of all foreign subsidiary earnings (excluding state and FIN 48 tax impacts) and a non-cash charge to establish a valuation allowance against a significant portion of the U.S. deferred tax assets related to carryforward of foreign tax credits, each due to the enactment in December 2017 of Tax Cuts and Jobs Act of 2017 (the “Act”). Partially offsetting this non-recurring tax cost in 2017, the reduction of the U.S. Federal tax rate from 35% to 21% percent in 2018 resulted in lower tax expense of $8.6$60.1 million.
On January 15, 2019, Natuswe announced the implementation of a new organizational structure designed to improve operational performance and make itus a stronger, more profitable company.
Application of Critical Accounting Policies
We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In so doing, we must often make estimates and use assumptions that can be subjective and, consequently, our actual results could differ from those estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable.
We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments. The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities, revenue, expenses, and related disclosures as of the date of the financial statements and during the reporting period.
Revenue recognition
Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of control of devices, supplies, or services. Revenue is measured as the amount of consideration the Company expectswe expect to receive in exchange for transferring goods or providing services.
For the majority of devices and supplies, the Company transferswe transfer control and recognizes revenue when products ship from the warehouse to the customer. The CompanyWe generally doesdo not provide rights of return on devices and supplies. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue.
Depending on the terms of the arrangement, the Companywe may also defer the recognition of a portion of the consideration received because it haswe have to satisfy a future obligation (e.g. installation). Judgment is required to determine the standalone selling price (“SSP”) for each distinct performance obligation. The Company’sOur estimate of SSP is a point estimate. The estimate is
calculated annually for each performance obligation that is not sold separately. In instances where SSP is not directly observable, such as when the Company doeswe do not sell the product or service separately, the SSP is determined using information that may include market conditions and other observable inputs.
For products containing embedded software, the Company determinedwe determine the hardware and software components function together to deliver the products' essential functionality and are considered a combined performance obligation. Revenue recognition policies for sales of these products are substantially the same as for other tangible products.
Acquisition Accounting
We have made a number of acquisitions in the past and may continue to make acquisitions in the future. We account for acquired business combinations using the acquisition method of accounting. The assets acquired and liabilities assumed are recorded based on their respective fair values at the date of acquisition, with limited exceptions.acquisition. Valuations are generally completed for business acquisitions using a discounted cash flow analysis. The most significant estimates and assumptions inherent in a discounted cash flow analysis include the amount and timing of projected future cash flows, the discounted rate used to measure the risks inherent in the future cash flows, the assessment of the asset's life cycle, and the competitive and other trends impacting the asset, including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. The excess of the fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill.
Determining the useful life of an intangible asset also requires judgment, as different types of intangibles assets will have different useful lives and certain assets may even be considered to have indefinite useful lives. Useful life is the period over which the intangible asset is expected to contribute directly and indirectly to our future cash flows. We determine the useful lives of intangible assets based on a number of factors, such as legal, regulatory, or contractual provisions that may limit the useful life, and the effects of obsolescence, anticipated demand, existence or absence of competition, and other economic factors on useful life.
Inventory Valuation
Inventories are carried at the lower of cost or net realizable value, with cost being determined using the first-in, first-out method. The carrying value of the Company's inventoriesour inventory is reduced for any difference between cost and estimated net realizable value of the inventory. We determine net realizable value by evaluating ending inventories for excess quantities, obsolescence, and other factors that could impact our ability to consume inventory for its intended use. Our evaluation of includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product. Adjustments to the value of inventory establish a new cost basis and are considered permanent even if circumstances later suggest that increased carrying amounts are recoverable. If demand is higher than expected, Natuswe may sell inventory that had previously been written down.
Results of Operations
The following table sets forth for the periods indicated selected consolidated statement of income data as a percentage of total revenue. Our historical operating results are not necessarily indicative of the results for any future period.
Percent of Revenue Years Ended December 31, | Percent of Revenue Years Ended December 31, | |||||||||||||||
| 2018 | 2017 | 2016 | 2019 | 2018 | 2017 | |||||||||||
| Revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||
| Cost of revenue | 41.1 | % | 42.6 | % | 37.9 | % | 39.7 | % | 41.1 | % | 42.6 | % | ||||
| Intangibles amortization | 1.7 | % | 1.3 | % | 0.6 | % | 1.4 | % | 1.7 | % | 1.3 | % | ||||
| Gross profit | 57.3 | % | 56.1 | % | 61.5 | % | 58.9 | % | 57.3 | % | 56.1 | % | ||||
| Operating expenses: | ||||||||||||||||
| Marketing and selling | 25.7 | % | 25.2 | % | 22.2 | % | 26.1 | % | 25.7 | % | 25.2 | % | ||||
| Research and development | 11.6 | % | 10.3 | % | 8.8 | % | 11.9 | % | 11.6 | % | 10.3 | % | ||||
| General and administrative | 13.3 | % | 14.9 | % | 13.3 | % | 12.0 | % | 13.3 | % | 14.9 | % | ||||
| Intangibles amortization | 4.3 | % | 3.8 | % | 2.4 | % | 3.1 | % | 4.3 | % | 3.8 | % | ||||
| Restructuring | 7.0 | % | 0.2 | % | 0.4 | % | 9.0 | % | 7.0 | % | 0.2 | % | ||||
| Total operating expenses | 61.9 | % | 54.4 | % | 47.0 | % | 62.1 | % | 61.9 | % | 54.4 | % | ||||
| Income (loss) from operations | (4.6 | )% | 1.7 | % | 14.5 | % | (3.2 | )% | (4.6 | )% | 1.7 | % | ||||
| Other expense, net | (1.5 | )% | (0.7 | )% | (0.1 | )% | (1.1 | )% | (1.5 | )% | (0.7 | )% | ||||
| Income before provision for income tax | (6.1 | )% | 1.0 | % | 14.4 | % | ||||||||||
| Provision for income tax expense | (1.8 | )% | 5.1 | % | 3.2 | % | ||||||||||
| Net income (loss) | (4.3 | )% | (4.1 | )% | 11.2 | % | ||||||||||
| Income (loss) before provision (benefit) for income tax | (4.3 | )% | (6.1 | )% | 1.0 | % | ||||||||||
| Provision (benefit) for income tax expense | (1.1 | )% | (1.8 | )% | 5.1 | % | ||||||||||
| Net loss | (3.2 | )% | (4.3 | )% | (4.1 | )% | ||||||||||
Comparison of 2019 and 2018
Revenue
| Years ended December 31, | ||||||||||
| 2019 | 2018 | Change | ||||||||
| Neuro | ||||||||||
| Devices and Systems | $ | 220,306 | $ | 200,762 | 10 | % | ||||
| Supplies | 66,059 | 67,025 | (1 | )% | ||||||
| Services | 871 | 12,000 | (93 | )% | ||||||
| Total Neuro Revenue | 287,236 | 279,787 | 3 | % | ||||||
| Newborn Care | ||||||||||
| Devices and Systems | 53,465 | 72,807 | (27 | )% | ||||||
| Supplies | 38,264 | 40,669 | (6 | )% | ||||||
| Services | 19,183 | 20,396 | (6 | )% | ||||||
| Total Newborn Care Revenue | 110,912 | 133,872 | (17 | )% | ||||||
| Hearing & Balance | ||||||||||
| Devices and Systems | $ | 92,050 | $ | 110,597 | (17 | )% | ||||
| Supplies | 4,977 | 6,635 | (25 | )% | ||||||
| Services | — | — | — | % | ||||||
| Total Hearing & Balance Revenue | 97,027 | 117,232 | (17 | )% | ||||||
| Total Revenue | $ | 495,175 | $ | 530,891 | (7 | )% | ||||
For the year ended December 31, 2019, Neuro revenue increased by 3% compared to the prior year. Devices and Systems revenue increased by 10% compared to the prior year due primarily to growth in EEG sales. Supplies revenue for 2019 decreased 1%, which was driven by declines in our international markets. Services revenue from GND decreased 93% compared to the prior year due to our exit from this business in January 2019.
For the year ended December 31, 2019, Newborn Care revenue decreased by 17% compared to the prior year. Devices and Systems revenue decreased by 27%. The decrease is primarily due to the divestiture of Medix, exit from our balance and mobility product line, and planned product line rationalization. Supplies revenue decreased 6% compared to the prior year related to divestiture of Medix business and product line rationalization. Services revenue decreased by 6% compared to the prior year
primarily due to a lower collection per screen and decrease in screening volume on our Peloton hearing screening service, which was exited as of December 31, 2019.
For the year ended December 31, 2019, Hearing & Balance revenue decreased 17% compared to the prior year. Revenue from Devices and Systems decreased 17% and revenue from Supplies decreased 25% in 2019 compared to 2018. The overall decline in Hearing & Balance was driven by the impact of product rationalization and ship holds on some products.
Cost of Revenue and Gross Profit
| Years ended December 31, | |||||||
| 2019 | 2018 | ||||||
| Revenue | $ | 495,175 | $ | 530,891 | |||
| Cost of revenue | 196,551 | 217,952 | |||||
| Intangibles amortization | 6,916 | 8,924 | |||||
| Gross profit | 291,708 | 304,015 | |||||
| Gross profit percentage | 58.9 | % | 57.3 | % | |||
For the year ended December 31, 2019, our gross profit as a percentage of sales increased by 160 basis points compared to the prior year. This increase was primarily attributable to cost reductions in our operations overhead and our exit from lower margin businesses as a result of our corporate reorganization announced in January 2019 and a reduction in intangible amortization and restructuring costs incurred in 2018 related to business line exits.
Operating Costs
| Years ended December 31, | |||||||
| 2019 | 2018 | ||||||
| Marketing and selling | $ | 129,109 | $ | 136,680 | |||
| Percentage of revenue | 26.1 | % | 25.7 | % | |||
| Research and development | $ | 58,733 | $ | 61,482 | |||
| Percentage of revenue | 11.9 | % | 11.6 | % | |||
| General and administrative | $ | 59,649 | $ | 70,599 | |||
| Percentage of revenue | 12.0 | % | 13.3 | % | |||
| Intangibles amortization | $ | 15,144 | $ | 22,585 | |||
| Percentage of revenue | 3.1 | % | 4.3 | % | |||
| Restructuring | $ | 44,739 | $ | 37,231 | |||
| Percentage of revenue | 9.0 | % | 7.0 | % | |||
Marketing and Selling
Marketing and selling expenses as a percentage of revenue remained relatively flat in the year ended December 31, 2019 as compared to the prior year. The decrease in expense is mainly attributable to the benefits of our corporate reorganization initiated in January 2019.
Research and Development
Research and development expenses decreased during the year ended December 31, 2019 compared to the prior year. The decrease relates to lower compensation related expenses due to our corporate reorganization initiatives.
General and Administrative
General and administrative expenses decreased during the year ended December 31, 2019 compared to the prior year. This decrease was due to a reduction in employee expenses, consulting fees and travel expenses due to our corporate reorganization and exit from non-core businesses.
Intangibles Amortization
Intangibles amortization decreased in the year ended December 31, 2019 compared to the prior year. The decrease is related to our restructuring initiatives, which included an impairment charge of $5.6 million in 2018 related to the end of life of our Bio-Logic core technology that did not recur in 2019.
Restructuring
Restructuring costs increased during the year ended December 31, 2019 compared to the prior year. This increase was driven by the restructuring initiatives announced in January 2019. We recorded an impairment related to the sale of Medix, which included the recognition of deferred foreign currency related adjustments in accumulated other comprehensive income, of $24.8 million, net of tax, and an adjustment of $4.6 million for assets with a book value in excess of their fair market value. The increase was also driven by restructuring expenses incurred related to exiting the GND business and our restructuring initiatives.
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $5.6 million in the year ended December 31, 2019, compared to $7.7 million in the prior year. We reported $0.8 million of foreign currency exchange losses in the year ended December 31, 2019 versus $0.8 million of foreign currency losses in the prior year.Interest expense was $4.9 million in the year ended December 31, 2019 compared to $6.8 million in the prior year. The reduction in interest expense was driven by accelerated payments on our outstanding debt. Interest income was $0.3 million in both the year ended December 31, 2019 and the prior year.
Provision for Income Tax
The effective tax rate (“ETR”) for the year ended December 31, 2019 was 26.3% as compared to 28.9% for the prior year. Significant items that impact the effective tax rate are the change in geographic mix of income, adjustments and reversals of uncertain tax positions and SAB 118 adjustments arising from the 2017 Tax Act that were recorded in 2018.
Comparison of 2018 and 2017
Revenue
| Years ended December 31, | Years ended December 31, | |||||||||||||||||||
| 2018 | 2017 | Change | 2018 | 2017 | Change | |||||||||||||||
| Neuro | ||||||||||||||||||||
| Devices and Systems | $ | 200,767 | $ | 171,315 | 17 | % | $ | 200,762 | $ | 171,315 | 17 | % | ||||||||
| Supplies | 67,032 | 59,955 | 12 | % | 67,025 | 59,955 | 12 | % | ||||||||||||
| Services | 12,000 | 11,886 | 1 | % | 12,000 | 11,886 | 1 | % | ||||||||||||
| Total Neuro Revenue | 279,799 | 243,156 | 15 | % | 279,787 | 243,156 | 15 | % | ||||||||||||
| Newborn Care | ||||||||||||||||||||
| Devices and Systems | 63,549 | 77,573 | (18 | )% | 72,807 | 89,027 | (18 | )% | ||||||||||||
| Supplies | 39,622 | 43,732 | (9 | )% | 40,669 | 43,928 | (7 | )% | ||||||||||||
| Services | 20,396 | 22,325 | (9 | )% | 20,396 | 22,325 | (9 | )% | ||||||||||||
| Total Newborn Care Revenue | 123,567 | 143,630 | (14 | )% | 133,872 | 155,280 | (14 | )% | ||||||||||||
| Otometrics | ||||||||||||||||||||
| Hearing & Balance | ||||||||||||||||||||
| Devices and Systems | $ | 119,269 | $ | 107,769 | 11 | % | 110,597 | 75,466 | 47 | % | ||||||||||
| Supplies | 8,256 | 6,415 | 29 | % | 6,635 | 27,068 | (75 | )% | ||||||||||||
| Services | — | — | — | % | — | — | — | % | ||||||||||||
| Total Otometrics Revenue | 127,525 | 114,184 | 12 | % | ||||||||||||||||
| Total Hearing & Balance Revenue | 117,232 | 102,534 | 14 | % | ||||||||||||||||
| Total Revenue | $ | 530,891 | $ | 500,970 | 6 | % | $ | 530,891 | $ | 500,970 | 6 | % | ||||||||
For the year ended December 31, 2018, Neuro revenue increased by 15% compared to the prior year. Devices and Systems revenue increased by 17% compared to the prior year due primarily to the addition of acquired Neurosurgery products and growth in EEG sales. Supplies revenue for 2018 increased 12%, which was also driven by the addition of our Neurosurgery business and organic growth in our Neurodiagnostic supply business. Services revenue from GND increased 1% compared to the prior year.
For the year ended December 31, 2018, Newborn Care revenue decreased by 14% compared to the prior year. Devices and Systems revenue decreased by 18%. The decrease is primarily due to the recognition of $10.0 million of revenue in the first half of 2017 from our contract with the government of Venezuela, which did not reoccur in 2018. We also experienced a one-timeone-
time shipment of neoBLUE blanket backlog in the first quarter of 2017 and a one-time shipment of hearing devices and supplies to China, Japan, and Australia in the second quarter of 2017. Supplies revenue decreased 9%7% compared to the prior year related to revenue contract with the government of Venezuela, which did not reoccur in 2018, as well as product line rationalization. Services revenue decreased by 9% compared to the prior year primarily due to a lower collection per screen on our Peloton hearing screening service.
For the year ended December 31, 2018, OtometricsHearing & Balance revenue increased 12%14% compared to the prior year. Revenue from Devices and Systems increased 11%47% and revenue from Supplies increased 29%decreased 75% in 2018 compared to 2017. The overall growth in OtometricsHearing & Balances was driven by increased market share primarily in Europe and China. In addition to increased market share, OtometricsHearing & Balance also benefited from favorable exchanges rates and the launch of our new Otoscan®Otoscan product in 2018.
Cost of Revenue and Gross Profit
| Years ended December 31, | |||||||
| 2018 | 2017 | ||||||
| Revenue | $ | 530,891 | $ | 500,970 | |||
| Cost of revenue | 217,952 | 213,376 | |||||
| Intangibles amortization | 8,924 | 6,380 | |||||
| Gross profit | 304,015 | 281,214 | |||||
| Gross profit percentage | 57.3 | % | 56.1 | % | |||
For the year ended December 31, 2018, our gross profit as a percentage of sales increased by 1.5%1.2% compared to the prior year. This increase was primarily attributable to the improvement in Newborn Care gross profit, which was lower in the prior year
due to sales to the government of Venezuela which carry a lower gross margin. We also experienced an increase on gross profit on our Neurosurgery products where we experienced higher sales in the U.S. which carry higher margins.
Operating Costs
| Years ended December 31, | Years ended December 31, | |||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||
| Marketing and selling | $ | 136,680 | $ | 126,166 | $ | 136,680 | $ | 126,166 | ||||||
| Percentage of revenue | 25.7 | % | 25.2 | % | 25.7 | % | 25.2 | % | ||||||
| Research and development | $ | 61,482 | $ | 51,822 | $ | 61,482 | $ | 51,822 | ||||||
| Percentage of revenue | 11.6 | % | 10.3 | % | 11.6 | % | 10.3 | % | ||||||
| General and administrative | $ | 70,599 | $ | 74,424 | $ | 70,599 | $ | 74,424 | ||||||
| Percentage of revenue | 13.3 | % | 14.9 | % | 13.3 | % | 14.9 | % | ||||||
| Intangibles amortization | $ | 22,585 | $ | 19,171 | ||||||||||
| Intangibles Amortization | $ | 22,585 | $ | 19,171 | ||||||||||
| Percentage of revenue | 4.3 | % | 3.8 | % | 4.3 | % | 3.8 | % | ||||||
| Restructuring | $ | 37,231 | $ | 914 | $ | 37,231 | $ | 914 | ||||||
| Percentage of revenue | 7.0 | % | 0.2 | % | 7.0 | % | 0.2 | % | ||||||
Marketing and Selling
Marketing and selling expenses as a percentage of revenue remained relatively flat in the year ended December 31, 2018 as compared to 2017.the prior year. The increase in expense in 2018 areis for incremental costs of payroll, commissions, and travel associated with higher revenue.
Research and Development
Research and development expenses increased during the year ended December 31, 2018 compared to the prior year. The increase relates to increased spend on new product development, including Otoscan®Otoscan and RetCam products, and the addition of Neurosurgery products. These increases were partially offset by a reduction in spend related to remediation activities within our Newborn Care business.
General and Administrative
General and administrative expenses decreased during the year ended December 31, 2018 compared to the prior year. This decrease was due to a reduction in bad debt expense related to our GND and Peloton businesses.
Intangibles Amortization
Intangibles amortization increased in the year ended December 31, 2018 compared to 2017.the prior year. The increase is related to the impairment charge incurred in 2018 in relation to an end of life decision on our Bio-logic core technology of $5.6 million. This impairment charge was partially offset by purchase accounting adjustments in 2017 related to our Integra and RetCam acquisitions which did not recur in 2018.
Restructuring
Restructuring costs increased during the year ended December 31, 2018 compared to the prior year. This increase included costs associated with the Company'sour executive management transition, which were approximately $10.0 million and were primarily comprised of accelerated vesting of stock compensation and severance expense. In 2018 we experienced impairment charges associated with exiting two of our non-core businesses, GND and Neurocom, which were categorized as restructuring expenses. We recorded a $14.8 million goodwill impairment charge related to GND. Impairment charges were also recorded for intangible and fixed assets related to GND and Neurocom, which totaled $2.8 million. Restructuring expenses were also incurred in 2018 in relation to the announcement of our new organizational structure, "One Natus."
Other Income (Expense), net
Other income (expense), net consists of interest income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other expense, net of $7.7 million in the year ended December 31, 2018, compared to $3.6 million in 2017.the prior year. We reported $0.8 million of foreign currency exchange losses in the year ended December 31, 2018 versus $1.0 million of foreign currency gains in 2017.the prior year.This increase was driven primarily by the changing value of foreign currencies in which we transact. Interest expense was $6.8 million
in the year ended December 31, 2018 compared to $5.1 million in 2017the prior year related to interest expense payments on our outstanding debt while interest income of $0.3 million in the year ended December 31, 2018 was $0.1 million less than the amount reported for 2017.the prior year.
Provision for Income Tax
The effective tax rate (“ETR”) for the year ended December 31, 2018 was 28.9% as compared to 494.0% for 2017.the prior year. The significantly lower effective rate in the year ended December 31, 2018 compared with 2017the prior year is primarily due to the impacts of the 2017 Tax Act, including the repatriation tax on accumulated foreign earnings and re-measurement of net deferred tax assets recorded in the prior year, a reduction in withholding taxes from distribution of income, and reduction in the U.S. Federal corporate rate from 35% to 21%.
| Years ended December 31, | ||||||||||
| 2017 | 2016 | Change | ||||||||
| Neuro | ||||||||||
| Devices and Systems | $ | 171,315 | $ | 168,200 | 2 | % | ||||
| Supplies | 59,955 | 58,681 | 2 | % | ||||||
| Services | 11,886 | 11,641 | 2 | % | ||||||
| Total Neuro Revenue | 243,156 | 238,522 | 2 | % | ||||||
| Newborn Care | ||||||||||
| Devices and Systems | 77,573 | 72,562 | 7 | % | ||||||
| Supplies | 43,732 | 47,674 | (8 | )% | ||||||
| Services | 22,325 | 23,134 | (3 | )% | ||||||
| Total Newborn Care Revenue | 143,630 | 143,370 | — | % | ||||||
| Otometrics | ||||||||||
| Devices and Systems | 107,769 | — | — | % | ||||||
| Supplies | 6,415 | — | — | % | ||||||
| Services | — | — | — | % | ||||||
| Total Otometrics Revenue | 114,184 | — | — | % | ||||||
| Total Revenue | $ | 500,970 | $ | 381,892 | 31 | % | ||||
| Years ended December 31, | |||||||
| 2017 | 2016 | ||||||
| Revenue | $ | 500,970 | $ | 381,892 | |||
| Cost of revenue | 213,376 | 144,632 | |||||
| Intangibles amortization | 6,380 | 2,327 | |||||
| Gross profit | 281,214 | 234,933 | |||||
| Gross profit percentage | 56.1 | % | 61.5 | % | |||
| Years ended December 31, | |||||||
| 2017 | 2016 | ||||||
| Marketing and selling | $ | 126,166 | $ | 84,834 | |||
| Percentage of revenue | 25.2 | % | 22.2 | % | |||
| Research and development | $ | 51,822 | $ | 33,443 | |||
| Percentage of revenue | 10.3 | % | 8.8 | % | |||
| General and administrative | $ | 74,424 | $ | 50,877 | |||
| Percentage of revenue | 14.9 | % | 13.3 | % | |||
| Intangibles Amortization | $ | 19,171 | $ | 8,983 | |||
| Percentage of revenue | 3.8 | % | 2.4 | % | |||
| Restructuring | $ | 914 | $ | 1,536 | |||
| Percentage of revenue | 0.2 | % | 0.4 | % | |||
Liquidity and Capital Resources
Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing and to raise capital. Therefore, liquidity cannot be considered separately from capital resources that consist of our current funds and the potential to increase those funds in the future. We plan to use these resources in meeting our commitments and in achieving our business objectives.
We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating requirements for the foreseeable future.
As of December 31, 2018,2019, we had cash and cash equivalents outside the U.S. in certain of our foreign operations of $46.8$51.0 million. We intend to permanently reinvest this cash held by our foreign subsidiaries except for Excel-Tech and Natus Ireland subsidiaries, which we intend to repatriate. If, however, a portion of these permanently reinvested funds were needed and distributed to our operations in the United States, we may be subject to additional U.S. income taxes and foreign withholding taxes depending on facts and circumstances at the time of distribution. The amount of taxes due would depend on the amount and manner of repatriation, as well as the location from where the funds were repatriated.
On September 23, 2016, we entered into a Credit Agreement with JP Morgan Chase Bank (“JP Morgan”) and, Citibank, NA (“Citibank”) and Wells Fargo Bank, National Association (“Wells Fargo”). The Credit Agreement provides for an aggregate $150.0 million of secured revolving credit facility (the “Credit Facility”). On September 15, 2017, we exercised our right to increase the amount available under the facility by $75.0 million, bringing the aggregate revolving credit facility to $225.0 million. The Credit Agreement contains covenants, including covenants relating to maintenance of books and records, financial reporting and notification, compliance with laws, maintenance of properties and insurance, and limitations on guaranties,
investments, issuance of debt, lease obligations and capital expenditures. The Credit Agreement provides for events of default, including failure to pay any principal or interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. The Company hasWe have no other significant credit facilities. As of December 31, 20182019 we had $105.0$55.0 million outstanding under the Credit Facility.
| December 31, 2018 | December 31, 2017 | December 31, 2016 | December 31, 2019 | December 31, 2018 | December 31, 2017 | |||||||||||||||||
| Cash, cash equivalents, and investments | $ | 56,373 | $ | 88,950 | $ | 247,570 | $ | 63,297 | $ | 56,373 | $ | 88,950 | ||||||||||
| Debt | 104,474 | 154,283 | 140,000 | 54,665 | 104,474 | 154,283 | ||||||||||||||||
| Working capital | 152,329 | 213,491 | 325,858 | 126,928 | 152,329 | 213,491 | ||||||||||||||||
| Year Ended | Year Ended | |||||||||||||||||||||
| December 31, 2018 | December 31, 2017 | December 31, 2016 | December 31, 2019 | December 31, 2018 | December 31, 2017 | |||||||||||||||||
| Net cash provided by operating activities | $ | 33,020 | $ | 19,726 | $ | 72,687 | $ | 60,060 | $ | 33,020 | $ | 19,726 | ||||||||||
| Net cash used in investing activities | (8,389 | ) | (160,935 | ) | (53,264 | ) | (5,339 | ) | (8,389 | ) | (160,935 | ) | ||||||||||
| Net cash provided by (used in) financing activities | (49,512 | ) | 5,826 | 118,417 | (48,532 | ) | (49,512 | ) | 5,826 | |||||||||||||
Comparison of 2019, 2018, 2017, and 20162017
During 2019 cash generated from operating activities of $60.1 million was the result of $15.7 million of net loss, non-cash adjustments to net loss of $63.2 million, and net cash outflows of $12.5 million from changes in operating assets and liabilities. The non-cash adjustments were $30.7 million of depreciation and amortization expense, $24.6 million of impairment for the sale of Medix, $8.4 million from share-based compensation, $2.9 million of warranty reserves, and $1.6 million of accounts receivable reserves, offset by deferred taxes of $5.4 million. Cash used in investing activities during the period was $5.3 million and consisted of cash used to acquire other property and equipment. Cash used in financing activities during the year ended December 31, 2019 was $48.5 million and consisted of repayments of $50.0 million of our outstanding debt under the Credit Facility, $1.7 million for taxes paid related to net share settlement of equity awards, $0.5 million of principal payments of financing lease liability, offset by proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases of $3.6 million.
During 2018 cash generated from operating activities of $33.0 million was the result of $22.9 million of net loss, non-cash adjustments to net loss of $70.1 million, and net cash outflows of $14.1 million from changes in operating assets and liabilities. The non-cash adjustments were $33.9 million of depreciation and amortization expense, $17.1 million from share-based compensation, a $14.8 million goodwill impairment charge related to GND, $8.2 million from intangible impairments, $6.9 million of accounts receivable reserves, and $2.2 million of warranty reserves, offset by deferred taxes of $13.7 million. Cash used in investing activities during the period was $8.4 million and consisted primarily of cash used to acquire other property and equipment of $7.9 million. Cash used in financing activities during the year ended December 31, 2018 was $49.5 million and consisted of repayments of $50.0 million of our outstanding debt under the Credit Facility, $5.6 million for repurchases of common stock under our share repurchase program, $5.2 million for taxes paid related to net share settlement of equity awards, offset by proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases of $11.5 million.
During 2017 cash generated from operating activities of $19.7 million was the result of $20.3 million of net loss, non-cash adjustments to net loss of $60.6 million, and net cash outflows of $20.6 million from changes in operating assets and liabilities. The non-cash adjustments were $30.1 million of depreciation and amortization expense, $10.0 million of accounts receivable reserves, $9.4 million from share-based compensation, $5.4 million of warranty reserves, $4.0 of deferred taxes and $1.7 million from intangible impairments. The change in operating assets and liabilities was driven primarily by an increase in accounts receivable and lower collections during the year compared to the prior year, and a decrease in deferred revenue related to the Venezuelan contract, partially offset by an increase in accrued liabilities for the transition tax under the Act for the deemed repatriation of foreign earnings and decreases in inventories and other assets. Cash used in investing activities during the period was $161.1 million and consisted primarily of the acquisition of Otometrics for $143.6 million, net of cash, and the Integra Asset Acquisitionasset acquisition for $46.4 million, offset by sales of short-term investments of $34.0 million. Cash used to acquire other property and equipment was $4.1 million. Cash provided by financing activities during the year ended December 31, 2017 was $5.8 million and consisted of proceeds from borrowings under the Credit Facility of $60.0 million along with proceeds from stock option exercises and Employee Stock Purchase Program (“ESPP”) purchases of $3.5 million, offset by $45.0 million repayment of debt under the Credit Facility, $7.0 million for taxes paid related to net share settlement of equity awards, $3.0 million for contingent acquisition consideration, $2.3 million for repurchases of common stock under our share repurchase program, and $0.3 million of deferred debt issuance costs.
Future Liquidity
Our future liquidity and capital requirements will depend on numerous factors, including the:
Amount and timing of revenue;
Extent to which our existing and new products gain market acceptance;
Extent to which we make acquisitions;
Cost and timing of product development efforts and the success of these development efforts;
Cost and timing of marketing and selling activities; and
Availability of borrowings under line of credit arrangements and the availability of other means of financing.
Contractual Obligations
In the normal course of business, we enter into obligations and commitments that require future contractual payments. The commitments result primarily from purchase orders placed with contract vendors that manufacture some of the components used in our medical devices and related disposable supply products, purchase orders placed for employee benefits and outside services,
as well as commitments for leased office space, leased equipment, and bank debt. The following table summarizes our contractual obligations and commercial commitments as of December 31, 20182019 (in thousands):
| Payments Due by Period | Payments Due by Period | |||||||||||||||||||||||||||||||||||||
| Total | Less than 1 Year | 1-3 Years | 4-5 Years | More than 5 Years | Total | Less than 1 Year | 1-3 Years | 4-5 Years | More than 5 Years | |||||||||||||||||||||||||||||
| Unconditional purchase obligations | $ | 66,659 | $ | 64,729 | $ | 1,930 | $ | — | $ | — | $ | 44,955 | $ | 44,955 | $ | — | $ | — | $ | — | ||||||||||||||||||
| Operating lease obligations | 27,547 | 8,092 | 12,241 | 5,849 | 1,365 | |||||||||||||||||||||||||||||||||
| Bank debt | 105,000 | — | 105,000 | — | — | 55,000 | — | 55,000 | — | — | ||||||||||||||||||||||||||||
| Interest payments | 8,685 | 4,721 | 3,964 | — | — | 2,390 | 1,907 | 483 | — | — | ||||||||||||||||||||||||||||
| Repatriation tax | 6,919 | $ | 308 | $ | 1,259 | $ | 1,810 | $ | 3,542 | 9,113 | 797 | 1,751 | 3,830 | 2,735 | ||||||||||||||||||||||||
| Total | $ | 214,810 | $ | 77,850 | $ | 124,394 | $ | 7,659 | $ | 4,907 | $ | 111,458 | $ | 47,659 | $ | 57,234 | $ | 3,830 | $ | 2,735 | ||||||||||||||||||
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding. Included in the purchase obligations category above are obligations related to purchase orders for inventory purchases under our standard terms and conditions and under negotiated agreements with vendors. We expect to receive consideration (products or services) for these purchase obligations. The purchase obligation amounts do not represent all anticipated purchases in the future, but represent only those items for which we are contractually obligated. The table above does not include obligations under employment agreements for services rendered in the ordinary course of business.
We are not able to reasonably estimate the timing of any potential payments for uncertain tax positions under Accounting Standards Codification ("ASC") 740, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement 109. As a result, the preceding table excludes any potential future payments related to our ASC 740 liability for uncertain tax positions. See Note 17 of our Consolidated Financial Statements for further discussion on income taxes.
Quantitative and Qualitative Disclosures about Market Risk
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. We are exposed to interest rate risk on our LIBOR-indexed floating-rate debt. We have entered into an interest rate swap agreement to effectively covert a portion of our floating-rate debt to a fixed-rate. The principal objective of the swap contract is to reduce the variability of future earnings and cash flows associated with our floating-rate debt. We do not hold or issue derivative instruments for trading or other speculative purposes.
Foreign Exchange Rate Risk
We develop products in the U.S, Canada, Europe, and Argentina,Europe, and sell those products into more than 100 countries throughout the world. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Most of our sales in Europe and Asia are denominated in the U.S. Dollar and Euro, and with a portion of our sales denominated in the Canadian dollar Argentine peso and British pound. As our sales in currencies other than the U.S. dollar increase, our exposure to foreign currency fluctuations may increase.
In addition, changes in exchange rates also may affect the end-user prices of our products compared to those of our foreign competitors, who may be selling their products based on local currency pricing. These factors may make our products less competitive in some countries.
If the U.S. Dollar uniformly increased or decreased in strength by 10% relative to the currencies in which our sales were denominated, our net income would have correspondingly increased or decreased by an immaterial amount for the year ended December 31, 2018.
2019.
All of the potential changes noted above are based on sensitivity analyses performed on our financial position as of December 31, 2018.2019. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.
Interest Rate Risk
As of December 31, 2018,2019, accumulated other comprehensive income (loss) related to the interest rate swap agreement included a net unrealized loss of approximately $61$143 thousand, net of tax, which will be recognized in interest expense after the following 12 months, at the then current values on a pre-tax basis. See Note 1112 to these Condensed Consolidated Financial Statements for additional discussion on our financial instruments and derivatives.
Interest Rate Risk Sensitivity Analysis
Our remaining indebtedness is at variable rates of interest. Accordingly, changes in interest rates would impact our results of operations in future periods. Based on a sensitivity analysis on actual rates experienced during 2018,2019, a hypothetical increase in interest rates of 50 basis points would have resulted in increased interest expense of $0.6$0.4 million ofduring the year ended December 31, 2018.2019.
In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement (Topic 813), Disclosure Framework-Changes to the Consolidated Financial Statements contained hereinDisclosure Requirements for Fair Value Measurement. This update amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosure. For calendar year-end entities, the update will be effective for annual periods beginning January 1, 2020, and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period. As the standard relates only to disclosures, we do not expect the adoption to have a full descriptionmaterial impact on our consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), Simplifying the Accounting for Income Tax. This update includes removal of recentcertain exceptions to the general principles of ASC 740, Income taxes, and simplification in several other areas such as accounting pronouncements includingfor franchise tax (or similar tax) that is partially based on income. The ASU is effective for us on January 1, 2021. We are in the respective expected datesprocess of adoption and effectsevaluating the impact of this standard on results of our operations andconsolidated financial condition.statements.
Cautionary Information Regarding Forward Looking Statements
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated. Forward-looking statements can be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. These forward-looking statements within Item 7 include, without limitation, statements regarding our ability to capitalize on improving market conditions, the sufficiency of our current cash, cash equivalents and short-termshort-
term investment balances, any cash generated from operations to meet our ongoing operating and capital requirements for the foreseeable future, outcomes of new product development, improved operations performance and profitability as the result of restructuring activities, and our intent to acquire additional technologies, products or businesses.
Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results predicted in the forward-looking statements as well as our future financial condition and results of operations to differ materially from our historical results or currently anticipated results. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A of this report for a description of risks and uncertainties. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
The information required by this Item is set forth in the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk, and is incorporated by reference in this section.
ITEM 8. Financial Statements and Supplementary Data
The Consolidated Financial Statements and Supplementary Data required by this Item are set forth where indicated in Item 15 of this report.
Selected Quarterly Financial Data (Unaudited)
The following table presents our operating results for each of the eight quarters in the period ending December 31, 2018.2019. The information for each of these quarters is unaudited and has been prepared on the same basis as our audited financial statements appearing elsewhere in this report.
In the opinion of our management all necessary adjustments, including normal recurring adjustments, have been included to present fairly the unaudited quarterly results when read in conjunction with our audited Consolidated Financial Statements and the related notes appearing elsewhere in this report. These operating results are not necessarily indicative of the results of any future period.
| Quarters Ended | Quarters Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 | December 31, 2017 | September 30, 2017 | June 30, 2017 | March 31, 2017 | December 31, 2019 | September 30, 2019 (1) | June 30, 2019 (1) | March 31, 2019 (1) | December 31, 2018 | September 30, 2018 | June 30, 2018 | March 31, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||
| (in thousands, except per amounts) | (in thousands, except per amounts) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 140,991 | $ | 130,638 | $ | 130,653 | $ | 128,609 | $ | 131,440 | $ | 122,643 | $ | 122,227 | $ | 124,660 | $ | 131,416 | $ | 123,463 | $ | 125,539 | $ | 114,757 | $ | 140,991 | $ | 130,638 | $ | 130,653 | $ | 128,609 | ||||||||||||||||||||||||||||||
| Cost of revenue | 58,103 | 51,583 | 52,897 | 55,369 | 54,762 | 47,112 | 54,589 | 56,913 | 49,259 | 48,389 | 52,393 | 46,510 | 58,103 | 51,583 | 52,897 | 55,369 | ||||||||||||||||||||||||||||||||||||||||||||||
| Intangibles amortization | 2,689 | 1,930 | 2,717 | 1,587 | 2,590 | 1,290 | 1,500 | 1,000 | 1,679 | 1,736 | 1,746 | 1,756 | 2,689 | 1,930 | 2,717 | 1,587 | ||||||||||||||||||||||||||||||||||||||||||||||
| Gross profit | 80,199 | 77,125 | 75,039 | 71,653 | 74,088 | 74,241 | 66,138 | 66,747 | 80,478 | 73,338 | 71,400 | 66,491 | 80,199 | 77,125 | 75,039 | 71,653 | ||||||||||||||||||||||||||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Marketing and selling | 34,206 | 33,200 | 33,401 | 35,872 | 31,060 | 32,537 | 30,354 | 32,215 | 32,268 | 30,787 | 32,324 | 33,729 | 34,206 | 33,200 | 33,401 | 35,872 | ||||||||||||||||||||||||||||||||||||||||||||||
| Research and development | 15,296 | 15,127 | 15,616 | 15,443 | 13,724 | 11,632 | 13,713 | 12,753 | 17,567 | 14,447 | 13,324 | 13,394 | 15,296 | 15,127 | 15,616 | 15,443 | ||||||||||||||||||||||||||||||||||||||||||||||
| General and administrative | 13,632 | 15,799 | 23,721 | 17,448 | 16,923 | 17,329 | 24,156 | 16,016 | 15,261 | 15,394 | 12,690 | 16,306 | 13,632 | 15,799 | 23,721 | 17,448 | ||||||||||||||||||||||||||||||||||||||||||||||
| Intangibles amortization | 9,151 | 4,477 | 4,151 | 4,806 | 7,330 | 3,882 | 3,885 | 4,074 | 3,844 | 3,751 | 3,763 | 3,786 | 9,151 | 4,477 | 4,151 | 4,806 | ||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring | 23,049 | 11,432 | 1,938 | 812 | — | 321 | 307 | 286 | 3,592 | 1,106 | 2,668 | 37,372 | 23,049 | 11,432 | 1,938 | 812 | ||||||||||||||||||||||||||||||||||||||||||||||
| Total operating expenses | 95,334 | 80,035 | 78,827 | 74,381 | 69,037 | 65,701 | 72,415 | 65,344 | 72,532 | 65,485 | 64,769 | 104,587 | 95,334 | 80,035 | 78,827 | 74,381 | ||||||||||||||||||||||||||||||||||||||||||||||
| Income from operations | (15,135 | ) | (2,910 | ) | (3,788 | ) | (2,728 | ) | 5,051 | 8,540 | (6,277 | ) | 1,403 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Income (loss) from operations | 7,946 | 7,853 | 6,631 | (38,096 | ) | (15,135 | ) | (2,910 | ) | (3,788 | ) | (2,728 | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Other income (expense), net | (2,754 | ) | (726 | ) | (2,398 | ) | (1,821 | ) | (2,300 | ) | 150 | (378 | ) | (1,039 | ) | (670 | ) | (1,609 | ) | (1,200 | ) | (2,112 | ) | (2,754 | ) | (726 | ) | (2,398 | ) | (1,821 | ) | |||||||||||||||||||||||||||||||
| Income before provision for income tax | (17,889 | ) | (3,636 | ) | (6,186 | ) | (4,549 | ) | 2,751 | 8,690 | (6,655 | ) | 364 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for income tax | (6,256 | ) | 1,940 | (3,609 | ) | (1,401 | ) | 9,845 | 17,203 | (1,621 | ) | 16 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Income (loss) before provision for (benefit from) income tax | 7,276 | 6,244 | 5,431 | (40,208 | ) | (17,889 | ) | (3,636 | ) | (6,186 | ) | (4,549 | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for (benefit from) income tax (e) | 4,266 | (1,987 | ) | 1,944 | (9,809 | ) | (6,256 | ) | 1,940 | (3,609 | ) | (1,401 | ) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | (11,633 | ) | $ | (5,576 | ) | $ | (2,577 | ) | $ | (3,148 | ) | $ | (7,094 | ) | $ | (8,513 | ) | $ | (5,034 | ) | $ | 348 | $ | 3,010 | $ | 8,231 | $ | 3,487 | $ | (30,399 | ) | $ | (11,633 | ) | $ | (5,576 | ) | $ | (2,577 | ) | $ | (3,148 | ) | ||||||||||||||||||
| Earnings per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings (loss) per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic | $ | (0.35 | ) | $ | (0.17 | ) | $ | (0.08 | ) | $ | (0.10 | ) | $ | (0.22 | ) | $ | (0.26 | ) | $ | (0.15 | ) | $ | 0.01 | $ | 0.09 | $ | 0.24 | $ | 0.10 | $ | (0.91 | ) | $ | (0.35 | ) | $ | (0.17 | ) | $ | (0.08 | ) | $ | (0.10 | ) | ||||||||||||||||||
| Diluted | $ | (0.35 | ) | $ | (0.17 | ) | $ | (0.08 | ) | $ | (0.10 | ) | $ | (0.22 | ) | $ | (0.26 | ) | $ | (0.15 | ) | $ | 0.01 | $ | 0.09 | $ | 0.24 | $ | 0.10 | $ | (0.91 | ) | $ | (0.35 | ) | $ | (0.17 | ) | $ | (0.08 | ) | $ | (0.10 | ) | ||||||||||||||||||
| Weighted average shares used in the calculation of net earnings per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Weighted average shares used in the calculation of net earnings (loss) per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic | 33,495 | 33,321 | 32,859 | 32,760 | 32,648 | 32,593 | 32,529 | 32,485 | 33,691 | 33,655 | 33,639 | 33,590 | 33,495 | 33,321 | 32,859 | 32,760 | ||||||||||||||||||||||||||||||||||||||||||||||
| Diluted | 33,495 | 33,321 | 32,859 | 32,760 | 32,648 | 32,593 | 32,529 | 33,040 | 33,829 | 33,738 | 33,690 | 33,590 | 33,495 | 33,321 | 32,859 | 32,760 | ||||||||||||||||||||||||||||||||||||||||||||||
(1) During the fourth quarter of 2019, we corrected certain previously reported financial information for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019 related to the accounting for certain research and development activities in an arrangement with a third party, certain invoice accruals, adjustments resulting from physical inventory observations, and the income tax impacts of these immaterial adjustments. The correction of the immaterial errors resulted in the following:
| (a) | Cost of revenue increased $0.1 million and $0.2 million for the quarters ended March 31, 2019 and June 30, 2019, respectively. Cost of revenue decreased $0.3 million for the quarter ended September 30, 2019. |
| (b) | Marketing and selling expense increased $0.1 million for the quarter ended June 30, 2019 and decreased $0.1 million for the quarter ended September 30, 2019. |
| (c) | Research and development expense increased $0.3 million, $0.6 million, and $0.3 million for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019 respectively. |
| (d) | General and administrative expense increased $0.3 million for the quarter ended September 30, 2019. |
| (e) | Provision for income tax decreased by $0.1 million, $0.2 million, and $6 thousand for the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019, respectively. |
ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
ITEM 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the rules of the Securities and Exchange Commission, “disclosure controls and procedures” are controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud due to inherent limitations of internal controls. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
Our management, with the participation of our chief executive officer and our chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our management, including our chief executive officer and chief financial officer, has concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of December 31, 2018.2019. This conclusion was based on the material weakness in our internal control over financial reporting further described below.
In light of the material weaknesses described below, management performed additional analysis and other procedures to ensure that our consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles (GAAP). Accordingly, management believes that the consolidated financial statements included in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rule 13a-15(f). Our management, under the supervision of our chief executive officer and our chief financial officer, assessed the effectiveness of ourExchange Act. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of December 31, 2018. In makingfinancial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of the inherent limitations of any system of internal control. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses of judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper overriding of controls. As a result of such limitations, there is risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this assessment,risk.
Based on our management usedevaluation under the criteria establishedset forth in Internal Control - IntegratedControl-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, (COSO). Based on our evaluation under the criteria set forth in the COSO Framework, our management concluded that as of December 31, 2018 our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting.
control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
As part of closing our books for the fourth quarter of 2019 we identified immaterial errors that indicated certain deficiencies existed in the Company’s internal control over financial reporting. Specifically, we did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of our controls over payroll accounts contributed to an error in the period end accrual. The Company has concluded that these deficiencies could have resulted in a material misstatement of the consolidated financial statements that would not have been prevented or detected on a timely basis, and as such, these control deficiencies result in a material weakness in internal control over financial reporting as of December 31, 2019.
Our independent registered public accounting firm, KPMG LLP, has audited the consolidated financial statements included in this Annual Report.Report on Form 10-K, and, as part of its audit, has issued an adverse opinion on the effectiveness of our internal control over financial reporting. KPMG LLP’s report is included herein in Part II, Item 9A of this Annual Report on Form 10-K.
Remediation Efforts to Address Material Weakness
To remediate the material weakness in our internal control over financial reporting described above, we plan to make substantive changes to enhance our design of controls intended to identify and assess contracts that include research and development activities and to aid in confirming the accuracy of our payroll accounts. Specifically, we plan to formalize a policy that provides guidance on proper identification, analysis and treatment of contracts that include research and development activities. We also intend to provide training to the finance team to ensure the policy is communicated, understood and followed. We intend to strengthen the control design for payroll accounts to require that specific review procedures be completed and to formalize the results of required review procedures in a checklist format including reviewer signoff. Additionally, we plan to institute a process to monitor changes to our control operators responsible for key controls over financial reporting and implement a control to verify that appropriate training is provided to new control operators to mitigate this risk of change in our system of control.
Changes in Internal Control over Financial Reporting
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on Internal Control Over Financial Reporting
We have audited Natus Medical Incorporated and subsidiariessubsidiaries’ (the “Company”)Company) internal control over financial reporting as of December 31, 2018,2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness, described below, on the achievement of the objectives of the control criteria, the Company has not maintained in all material respects, effective internal control over financial reporting as of December 31, 2018,2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”)(PCAOB), the consolidated balance sheets of the Company as of December 31, 20182019 and 2017,2018, the related consolidated statements of operations, and comprehensive income stockholders'(loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2018,2019, and the related notes and financial statement schedule II: Valuation and Qualifying Accounts (collectively, the “consolidatedconsolidated financial statements”)statements), and our report dated March 1, 20192, 2020 expressed an unqualified opinion on those consolidated financial statements.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment:
The Company did not have controls designed to identify and properly account for certain research and development activities related to an arrangement with a third party. Additionally, insufficient training provided to a new control operator and the design of one of the Company’s controls over payroll accounts contributed to an error in the period-end accrual.
The material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2019 consolidated financial statements, and this report does not affect our report on those consolidated financial statements.
Basis for Opinion
The Company'sCompany’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting.Reporting in Item 9A. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
(signed) KPMG LLP
San Francisco, California
March 1, 20192, 2020
ITEM 9B. Other Information
None.
PART III
We will provide information that is responsive to this Part III in our Definitive Proxy Statement for our 20192020 Annual Meeting of Stockholders (our “2019“2020 Proxy Statement”) or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Part III by reference.
ITEM 10. Directors, Executive Officers, and Corporate Governance
We will provide certain other information that is responsive to this Item 10 in our 20192020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 10 by reference.
Audit Committee and Audit Committee Financial Expert
The members of the Audit Committee of our Board of Directors are Kenneth E. Ludlum, Robert A. Gunst,Thomas J. Sullivan, and Joshua H. Levine.Alice D. Schroeder. Our Board of Directors has determined that Kenneth E. Ludlum is an audit committee financial expert as defined in Item 407(d) of Regulation S-K. All of the members of our audit committee are considered “independent” as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Exchange Act.
Code of Conduct and Ethics
We have a code of conduct and ethics that applies to all of our employees, including our principal executive officer, principal financial officer, and principal accounting officer or controller. This code of conduct and ethics is posted on our internet website. The internet address for our website is www.natus.com, and the code of conduct and ethics may be found in the “Governance” section of our “Investor” webpage.
We intend to satisfy the disclosure requirement under Item 10 of Form 8-K regarding certain amendments to, or waivers from, provisions of this code of conduct and ethics by posting such information on our website, at the address and location specified above, or as otherwise required by The NASDAQNasdaq Stock Market.
ITEM 11. Executive Compensation
We will provide information that is responsive to this Item 11 in our 20192020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 11 by reference.
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Equity Compensation Plan Information
The following table sets forth information about the number of shares of common stock that can be issued under our 20112018 Stock Awards Plan as amended, and our 2011 Employee Stock Purchase Plan as of December 31, 2018.2019.
| Plan Category | Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants, Awards and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants, Awards and Rights | Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (excluding securities reflected in the first column) | Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants, Awards and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants, Awards and Rights | Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (excluding securities reflected in the first column) | ||||||||||||||
| Equity compensation plans approved by security holders | 314,191 | $ | 24.50 | 457,088 | 247,029 | $ | 35.31 | 2,764,603 | ||||||||||||
| Equity compensation plans not approved by security holders | — | — | — | — | — | — | ||||||||||||||
| Total | 314,191 | 24.50 | 457,088 | 247,029 | 35.31 | 2,764,603 | ||||||||||||||
We will provide certain other information that is responsive to this Item 12 in our 20192020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 12 by reference.
ITEM 13. Certain Relationships and Related Transactions, and Director Independence
We will provide information that is responsive to this Item 13 in our 20192020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 13 by reference.
ITEM 14. Principal Accounting Fees and Services
We will provide information that is responsive to this Item 14 in our 20192020 Proxy Statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated into this Item 14 by reference.
PART IV
ITEM 15. Exhibits, Financial Statement Schedules
(a)(2) Financial Statement Schedule
SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2019, 2018 2017 and 20162017
(In thousands)
| Balance at Beginning of Period | Additions Charged to Expense | Deductions | Balance at End of Period | ||||||||||||
| Year ended December 31, 2019 | |||||||||||||||
| Allowance for doubtful accounts | $ | 6,960 | $ | 1,584 | $ | (1,160 | ) | $ | 7,384 | ||||||
| Valuation allowance | 637 | — | (31 | ) | 606 | ||||||||||
| Warranty reserve | 9,391 | 3,949 | (6,936 | ) | 6,404 | ||||||||||
| Year ended December 31, 2018 | |||||||||||||||
| Allowance for doubtful accounts | $ | 8,978 | $ | 6,423 | $ | (8,441 | ) | $ | 6,960 | ||||||
| Valuation allowance | 5,862 | — | (5,225 | ) | 637 | ||||||||||
| Warranty reserve | 10,995 | 4,487 | (6,091 | ) | 9,391 | ||||||||||
| Year ended December 31, 2017 | |||||||||||||||
| Allowance for doubtful accounts | $ | 4,182 | $ | 10,017 | $ | (5,221 | ) | $ | 8,978 | ||||||
| Valuation allowance | 3,706 | 2,156 | — | 5,862 | |||||||||||
| Warranty reserve | 10,670 | 5,370 | (5,045 | ) | 10,995 | ||||||||||
| Balance at Beginning of Period | Additions Charged to Expense | Deductions | Balance at End of Period | ||||||||||||
| Year ended December 31, 2018 | |||||||||||||||
| Allowance for doubtful accounts | $ | 8,978 | $ | 6,423 | $ | (8,441 | ) | $ | 6,960 | ||||||
| Valuation allowance | 5,862 | — | (5,225 | ) | 637 | ||||||||||
| Year ended December 31, 2017 | |||||||||||||||
| Allowance for doubtful accounts | $ | 4,182 | $ | 10,017 | $ | (5,221 | ) | $ | 8,978 | ||||||
| Valuation allowance | 3,706 | 2,156 | — | 5,862 | |||||||||||
| Year ended December 31, 2016 | |||||||||||||||
| Allowance for doubtful accounts | $ | 4,686 | $ | 1,123 | $ | (1,627 | ) | $ | 4,182 | ||||||
| Valuation allowance | 3,972 | — | (266 | ) | 3,706 | ||||||||||
(a)(3) Exhibits
The Exhibits listed in the Index to Exhibits, which appears immediately following the signature page and is incorporated herein by reference, are filed as part of this 10-K.
| Incorporated By Reference | Incorporated By Reference | |||||||||||||||||||||
| Exhibit No. | Exhibit | Filing | Exhibit No. | File No. | File Date | Exhibit | Filing | Exhibit No. | File No. | File Date | ||||||||||||
| 3.1 | Natus Medical Incorporated Amended and Restated Certificate of Incorporation | S-1 | 3.1.1 | 333-44138 | 8/18/2000 | Natus Medical Incorporated Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of July 25, 2001 | S-1 | 3.1.1 | 333-44138 | 8/18/2000 | ||||||||||||
| 3.2 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation | 8-K | 3.1 | 000-33001 | 9/13/2012 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of September 12, 2012 | 8-K | 3.1 | 000-33001 | 9/13/2012 | ||||||||||||
| 3.3 | Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock | 8-A | 3.1.2 | 000-33001 | 9/6/2002 | Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of June 5, 2019 | 8-K | 3.1 | 000-33001 | 6/7/2019 | ||||||||||||
| 3.4 | Amended and Restated Bylaws of Natus Medical Incorporated | 8-K | 3.1 | 000-33001 | 12/7/2018 | Second Amended and Restated Bylaws of Natus Medical Incorporated | 8-K | 3.1 | 000-33001 | 12/16/2019 | ||||||||||||
| 4.1 | Specimen stock certificate for shares of common stock, par value $0.001 per share | S-1/A | 4.1 | 333-44138 | 2/9/2001 | |||||||||||||||||
| 4.2 | Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock | 8-A | 3.1.2 | 000-33001 | 9/6/2002 | |||||||||||||||||
| 4.3 | Description of Common Stock | |||||||||||||||||||||
| 10.1 | Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers | S-1 | 10.1 | 333-44138 | 8/18/2000 | Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers | S-1 | 10.1 | 333-44138 | 8/18/2000 | ||||||||||||
| 10.1.1 | 2018 Equity Incentive Plan | 8-K | 10.1 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.2 | Form of Stock Option Awards Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.1 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.3 | Form of Restricted Stock Award Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.2 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.1* | 2018 Equity Incentive Plan | 8-K | 10.1 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.2* | Form of Stock Option Awards Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.1 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.3* | Form of Restricted Stock Award Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.2 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.4 | Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.3 | 000-33001 | 12/18/2018 | Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.3 | 000-33001 | 12/18/2018 | ||||||||||||
| 10.1.5 | Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.4 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.1.5* | Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan | 8-K | 10.1.4 | 000-33001 | 12/18/2018 | |||||||||||||||||
| 10.2* | Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan | 8-K | 10.1 | 000-33001 | 1/4/2006 | Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan | 8-K | 10.1 | 000-33001 | 1/4/2006 | ||||||||||||
| 10.2.1* | Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan | S-1 | 10.3.1 | 333-44138 | 8/18/2000 | Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan | S-1 | 10.3.1 | 333-44138 | 8/18/2000 | ||||||||||||
| 10.2.2* | Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan | 10-Q | 10.2 | 000-33001 | 8/9/2006 | Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan | 10-Q | 10.2 | 000-33001 | 8/9/2006 | ||||||||||||
| 10.2.3* | Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan | 10-K | 10.2.3 | 000-33001 | 3/14/2008 | Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan | 10-K | 10.2.3 | 000-33001 | 3/14/2008 | ||||||||||||
| 10.3* | Natus Medical Incorporated 2000 Director Option Plan | 10-Q | 10.02 | 000-33001 | 5/9/2008 | Natus Medical Incorporated 2000 Director Option Plan | 10-Q | 10.02 | 000-33001 | 5/9/2008 | ||||||||||||
| 10.3.1* | Form of Option Agreement under the 2000 Director Option Plan | S-1 | 10.4.1 | 333-44138 | 8/18/2000 | Form of Option Agreement under the 2000 Director Option Plan | S-1 | 10.4.1 | 333-44138 | 8/18/2000 | ||||||||||||
| 10.4* | Natus Medical Incorporated 2000 Supplemental Stock Option Plan | S-1 | 10.15 | 333-44138 | 2/9/2001 | Natus Medical Incorporated 2000 Supplemental Stock Option Plan | S-1 | 10.15 | 333-44138 | 2/9/2001 | ||||||||||||
| 10.4.1* | Form of Option Agreement for 2000 Supplemental Stock Option Plan | S-1 | 10.15.1 | 333-44138 | 2/9/2001 | Form of Option Agreement for 2000 Supplemental Stock Option Plan | S-1 | 10.15.1 | 333-44138 | 2/9/2001 | ||||||||||||
| 10.5* | Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder | 8-K | 10.2 | 000-33001 | 1/4/2006 | Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder | 8-K | 10.2 | 000-33001 | 1/4/2006 | ||||||||||||
| 10.6* | [Amended] 2011 Stock Awards Plan | 14-A | — | 000-33001 | 4/20/2011 | [Amended] 2011 Stock Awards Plan | 14-A | — | 000-33001 | 4/20/2011 | ||||||||||||
| 10.6.1* | Form of Stock Option Award Agreement under the [Amended] 2011 Stock Plan | 10-Q | 10.1 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.6.2* | Form of Restricted Stock Award Purchase Agreement | 10-Q | 10.2 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.6.3* | Form of Restricted Stock Unit Agreement | 10-Q | 10.3 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.7* | 2011 Employee Stock Purchase Plan | 14-A | — | 000-33001 | 4/20/2011 | |||||||||||||||||
| Incorporated By Reference | Incorporated By Reference | |||||||||||||||||||||
| Exhibit No. | Exhibit | Filing | Exhibit No. | File No. | File Date | Exhibit | Filing | Exhibit No. | File No. | File Date | ||||||||||||
| 10.6.1* | Form of Stock Option Award Agreement under the [Amended] 2011 Stock Plan | 10-Q | 10.1 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.6.2* | Form of Restricted Stock Award Purchase Agreement | 10-Q | 10.2 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.6.3* | Form of Restricted Stock Unit Agreement | 10-Q | 10.3 | 000-33001 | 11/7/2011 | |||||||||||||||||
| 10.7* | 2011 Employee Stock Purchase Plan | 14-A | — | 000-33001 | 4/20/2011 | |||||||||||||||||
| 10.7.1* | 2011 Employee Stock Purchase Plan Subscription Agreement | 14-A | — | 000-33001 | 4/20/2011 | 2011 Employee Stock Purchase Plan Subscription Agreement | 14-A | — | 000-33001 | 4/20/2011 | ||||||||||||
| 10.8* | Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer | 10-K | 10.10 | 000-33001 | 3/10/2009 | Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer | 10-K | 10.10 | 000-33001 | 3/10/2009 | ||||||||||||
| 10.8.1* | Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer | 10-K | 000-33001 | 3/16/2015 | Form of Amendment to Employment Agreement between Natus Medical Incorporated and each of its executive officers other than its Chief Executive Officer and Chief Financial Officer | 10-K | 000-33001 | 3/16/2015 | ||||||||||||||
| 10.9* | Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013 | 8-K | 99.1 | 000-33001 | 4/22/2013 | Amended employment agreement between Natus Medical Incorporated and its Chief Executive Officer, James B. Hawkins dated April 19, 2013 | 8-K | 99.1 | 000-33001 | 4/22/2013 | ||||||||||||
| 10.10* | Terms of Resignation between Natus Medical Incorporated and James B. Hawkins dated July 11, 2018 | 10-Q | 10.16 | 000-33001 | 8/8/2018 | Terms of Resignation between Natus Medical Incorporated and James B. Hawkins dated July 11, 2018 | 10-Q | 10.16 | 000-33001 | 8/8/2018 | ||||||||||||
| 10.11 | Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015 | 8-K | 10.1 | 000-33001 | 10/9/2015 | Credit Agreement between Natus Medical Incorporated and CitiBank, NA dated October 9, 2015 | 8-K | 10.1 | 000-33001 | 10/9/2015 | ||||||||||||
| 10.12 | Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015 | 10-Q | 000-33001 | 2/29/2016 | Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015 | 10-Q | 000-33001 | 2/29/2016 | ||||||||||||||
| 10.13 | Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015 | 10-Q | 10.2 | 000-33001 | 11/3/2016 | Amendment to Agreement For the Acquisition of Medical Devices between Medix ICSA and the Ministry of Health of the Republic of Venezuela dated October 15, 2015 | 10-Q | 10.2 | 000-33001 | 11/3/2016 | ||||||||||||
| 10.14 | Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A. | 10-Q | 10.1 | 000-33001 | 11/3/2016 | Credit Agreement, dated September 23, 2016, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A. | 10-Q | 10.1 | 000-33001 | 11/3/2016 | ||||||||||||
| 10.15 | Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company | 10-Q | 10.3 | 000-33001 | 11/3/2016 | Master Purchase Agreement, dated September 25, 2016, between GN Hearing A/S, GN Nord A/S and the Company | 10-Q | 10.3 | 000-33001 | 11/3/2016 | ||||||||||||
| 10.16* | Forms of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated August 24, 2018 | 8-K | 99.1 | 000-33001 | 8/29/2018 | Forms of Employment Agreement between Natus Medical Incorporated and Jonathan A. Kennedy dated August 24, 2018 | 8-K | 99.1 | 000-33001 | 8/29/2018 | ||||||||||||
| 10.17* | Form of Employment Agreement between Natus Medical Incorporated and Drew Davies dated October 1, 2018 | 10-Q | 10.18 | 000-33001 | 11/8/2018 | Form of Employment Agreement between Natus Medical Incorporated and Drew Davies dated October 1, 2018 | 10-Q | 10.18 | 000-33001 | 11/8/2018 | ||||||||||||
| 21.1 | Significant Subsidiaries of the Registrant | Significant Subsidiaries of the Registrant | ||||||||||||||||||||
| 23.1 | Consent of Independent Registered Public Accounting Firm | Consent of Independent Registered Public Accounting Firm | ||||||||||||||||||||
| 24.1 | Power of Attorney (included on signature page) | Power of Attorney (included on signature page) | ||||||||||||||||||||
| 31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||||||||||||||||||
| Incorporated By Reference | ||||||||||
| Exhibit No. | Exhibit | Filing | Exhibit No. | File No. | File Date | |||||
| 31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |||||||||
| 32.1 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |||||||||
| The following financial information from Natus Medical Incorporated Annual Report on Form 10-K for the fiscal year ended December 31, 2019, formatted in XBRL | ||||||||||
| The cover page of the Annual Report on Form 10-K formatted in Inline XBRL | ||||||||||
* Indicates a management contract or compensatory plan or arrangement
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.
NATUS MEDICAL INCORPORATED | ||
| By | /s/ JONATHAN A. KENNEDY | |
Jonathan A. Kennedy President and Chief Executive Officer | ||
| By | /s/ B. DREW DAVIES | |
B. Drew Davies Executive Vice President and Chief Financial Officer | ||
Dated: March 1, 20192, 2020
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jonathan A. Kennedy and B. Drew Davies and each of them acting individually, as his or her attorney-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacity and dates indicated:
| Signature | Title | Date | ||
/S/ JONATHAN A. KENNEDY | President and Chief Executive Officer (Principal Executive Officer) | March | ||
| (Jonathan A. Kennedy) | ||||
/S/ B. DREW DAVIES | Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer) | March | ||
| (B. Drew Davies) | ||||
/S/ BARBARA R. PAUL | Chairperson of the Board of Directors | March | ||
| (Barbara R. Paul) | ||||
/S/ | Director | March | ||
| (Lisa W. Heine) | ||||
/S/ JOSHUA H. LEVINE | Director | March | ||
| (Joshua H. Levine) | ||||
/S/ KENNETH E. LUDLUM | Director | March | ||
| (Kenneth E. Ludlum) | ||||
/S/ ALICE D. SCHROEDER | Director | March 2, 2020 | ||
| (Alice D. Schroeder) | ||||
/S/ THOMAS J. SULLIVAN | Director | March 2, 2020 | ||
| (Thomas J. Sullivan) | ||||
NATUS MEDICAL INCORPORATED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Natus Medical Incorporated:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Natus Medical Incorporated and subsidiaries (the Company) as of December 31, 20182019 and 2017,2018, the related consolidated statements of operations, and comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2018,2019, and the related notes and financial statement schedule II: Valuation and Qualifying Accounts (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 20182019 and 2017,2018, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2018,2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company'sCompany’s internal control over financial reporting as of December 31, 2018,2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 1, 20192, 2020 expressedan unqualifiedadverse opinion on the effectiveness of the Company'sCompany’s internal control over financial reporting.
Change in Accounting Principle
As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases due to the adoption of Financial Accounting Standards Board Accounting Standards Codification Topic 842, Leases, on a modified retrospective basis as of January 1, 2019.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company'sCompany’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Evaluation of net realizable value adjustments for inventory excess and obsolescence
As discussed in Notes 1 and 4 to the consolidated financial statements, the Company has inventory with a carrying value of $89.6 million at December 31, 2019, of which $71.4 million is classified as current and $18.2 million is classified as noncurrent. Within noncurrent inventory are service components for products the Company no longer sells and inventory purchased for lifetime buys, which are required by regulation given the nature of the Company’s products. The Company reduces the carrying value of inventory for any differences between its cost and estimated net realizable value. Net realizable value is estimated by evaluating ending inventories for excess quantities, obsolescence, and other factors that potentially impact the Company’s ability to consume inventory for its intended use. In making its estimate of net realizable value, the Company’s evaluation includes an analysis of historical sales by product, projections of future demand by product, and an analysis of obsolescence by product.
We identified the evaluation of net realizable value adjustments for inventory excess and obsolescence as a critical audit matter given the high degree of auditor judgement required. The degree of auditor judgment required was considered high given the inherent uncertainty in projecting future demand and complexity involved in assessing whether the Company’s analysis of historical sales by product, projections of future demand, and assessment of obsolescence effectively captured the subset of inventory requiring net realizable value adjustments.
The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company’s process to identify inventory subject to risk of excess and obsolescence and reduce this inventory to an estimate of net realizable value. In evaluating potential excess inventory, we compared on hand inventory to the Company’s estimate of future inventory consumption. We evaluated the estimate of future inventory consumption through an analysis of historical inventory usage by product and information obtained from the Company’s manufacturing planning department. We obtained internal and external product inspection reports to identify inventory subject to remediation and evaluated the Company’s assessment of obsolescence. We also compared the Company’s estimate of net realizable value adjustments for identified excess and obsolete to the prior period estimate and to actual inventory scrapping history.
(signed) KPMG LLP
We have served as the Company's auditor since 2014.
San Francisco, California
March 1, 20192, 2020
NATUS MEDICAL INCORPORATED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)
| December 31, | December 31, | |||||||||||||
| 2018 | 2017 | 2019 | 2018 | |||||||||||
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 56,373 | $ | 88,950 | $ | 63,297 | $ | 56,373 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $6,960 and $8,978 | 127,041 | 126,809 | ||||||||||||
| Accounts receivable, net of allowance for doubtful accounts of $7,384 and $6,960 | 115,889 | 127,041 | ||||||||||||
| Inventories | 79,736 | 71,529 | 71,368 | 79,736 | ||||||||||
| Prepaid expenses and other current assets | 22,625 | 18,340 | 19,195 | 22,625 | ||||||||||
| Total current assets | 285,775 | 305,628 | 269,749 | 285,775 | ||||||||||
| Property and equipment, net | 22,913 | 22,071 | 24,702 | 22,913 | ||||||||||
| Operating lease right-of-use assets | 15,046 | — | ||||||||||||
| Intangible assets, net | 139,453 | 172,582 | 114,799 | 139,453 | ||||||||||
| Goodwill | 147,644 | 172,998 | 146,367 | 147,644 | ||||||||||
| Deferred income tax | 22,639 | 10,709 | 30,355 | 22,639 | ||||||||||
| Other assets | 19,716 | 25,931 | 21,509 | 19,716 | ||||||||||
| Total assets | $ | 638,140 | $ | 709,919 | $ | 622,527 | $ | 638,140 | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 28,805 | $ | 25,242 | $ | 27,253 | $ | 28,805 | ||||||
| Current portion of long-term debt | 35,000 | — | 35,000 | 35,000 | ||||||||||
| Current portion of operating lease liabilities | 5,871 | — | ||||||||||||
| Accrued liabilities | 52,568 | 51,738 | 54,451 | 52,568 | ||||||||||
| Deferred revenue | 17,073 | 15,157 | 20,246 | 17,073 | ||||||||||
| Total current liabilities | 133,446 | 92,137 | 142,821 | 133,446 | ||||||||||
| Long-term liabilities: | ||||||||||||||
| Other liabilities | 19,845 | 21,995 | 17,616 | 19,845 | ||||||||||
| Long-term debt | 69,474 | 154,283 | 19,665 | 69,474 | ||||||||||
| Operating lease liabilities | 12,051 | — | ||||||||||||
| Deferred income tax | 16,931 | 19,407 | 14,251 | 16,931 | ||||||||||
| Total liabilities | 239,696 | 287,822 | 206,404 | 239,696 | ||||||||||
| Commitments and contingencies (Note 20) | ||||||||||||||
| Commitments and contingencies (Note 21) | ||||||||||||||
| Stockholders’ equity: | ||||||||||||||
| Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 33,804,379 in 2018 and 33,134,101 in 2017 | 334,215 | 316,577 | ||||||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2018 and in 2017 | — | — | ||||||||||||
| Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding 34,148,700 in 2019 and 33,804,379 in 2018 | 344,476 | 334,215 | ||||||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and in 2018 | — | — | ||||||||||||
| Retained earnings | 102,261 | 129,115 | 87,922 | 102,261 | ||||||||||
| Accumulated other comprehensive loss | (38,032 | ) | (23,595 | ) | (16,275 | ) | (38,032 | ) | ||||||
| Total stockholders’ equity | 398,444 | 422,097 | 416,123 | 398,444 | ||||||||||
| Total liabilities and stockholders’ equity | $ | 638,140 | $ | 709,919 | $ | 622,527 | $ | 638,140 | ||||||